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Activation of renin-angiotensin system and elevated levels of circulating and 
brain angiotensin II (AngII) has been implicated in the pathogenesis of neuro-
cardiovascular diseases, such as hypertension and heart failure. In central 
neurons AngII increases generation of reactive oxygen species (ROS), which in 
turn regulates neuronal ion channels. Previous studies have demonstrated that 
ion channels can also be regulated by protein kinases, such as calcium 
/calmodulin-dependent protein kinase II (CaMKII) as a downstream mediator of 
AngII signaling. In the heart, CaMKIIδ undergoes oxidation upon AngII 
stimulation and increased pro-oxidant conditions. However, the exact mechanism 
by which AngII and ROS regulate CaMKIIα, the major neuronal isoform, in central 
neurons is unclear. We hypothesized that overexpression of wild-type CaMKIIα in 
neurons exacerbates the AngII-mediated inhibition of neuronal ion channels and 




(CATH.a) neurons overexpression of wt-CaMKIIα significantly enhanced the 
AngII-mediated reduction in K+ current as compared to non-transduced and 
adenoviral control vector-transduced neurons. Overexpression of wt-CaMKIIα in 
brain subfornical organ sensitized mice to an immediate increase in blood 
pressure at an initial subpressor dose of chronic subcutaneous AngII infusion. 
We further hypothesized that mutation of redox-sensitive cysteine and 
methionine residues at positions 280 and 281 respectively of CaMKIIα will inhibit 
the potentiated AngII-signaling in neurons and the rise in blood pressure. 
Adenovrius-mediated expression of mut-CaMKIIα in CATH.a neurons resulted in 
a significant restoration of the potentiated AngII-mediated K+ current inhibition 
observed with wt-CaMKIIα overexpression. Further, mice with mut-CaMKIIα in 
the brain were prevented from the initial sensitization mechanism following 
subcutaneous AngII infusion and the peak AngII-induced blood pressure was 
also significantly attenuated as compared to mice with wt-CaMKIIα 
overexpression. Together, these studies indicate that redox-regulation of 
CaMKIIα is an important mechanism in AngII-downstream signaling in neurons 
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Chapter I: BACKGROUND 
 
Cardiovascular disease and hypertension 
 
Cardiovascular disease is the major cause of morbidity and mortality worldwide. 
The American Heart Association (AHA) reported in 2013 that cardiovascular 
disease and particularly heart disease is the leading cause of death specifically 
within the United States (1). Cardiovascular disorders include coronary heart 
disease (heart attacks), cerebrovascular disease (stroke), raised blood pressure 
(hypertension), peripheral arterial disease, congenital heart disease and heart 
failure. Hypertension is a key risk factor of cardiovascular disease and according 
to World Health Organization (WHO) approximately 17 million deaths each year 
are due to cardiovascular disease of which 9.4 million is attributable to 
complications of hypertension (2). The increasing occurrence of hypertension 
includes a growing geriatric population, and behavioral risk factors, such as 
unhealthy diet, lack of physical activity, poor stress management, and the use of 
tobacco and alcohol (2). Hypertension is considered as a “silent” invisible killer 
which impacts global public health concerns and is in constant progress due to 
the growing incidence of diabetes and obesity (2-4). Furthermore, uncontrolled 
hypertension is a risk for several cardiovascular disorders, including stroke, heart 





Blood pressure regulation and hypertension 
 
 
Blood pressure is the mean arterial pressure that is monitored and regulated by 
physiological mechanisms in the body. It is the force of blood that pushes against 
the arterial walls of the arteries as the heart pumps blood to the systemic tissues 
of the body. Blood pressure is commonly measured by a stethoscope and a 
sphygmomanometer (also referred to as a sphygmometer). It is attached to an 
inflatable air-bladder cuff to temporarily restrict blood flow and a mercury or 
mechanical manometer measures the pressure. Blood pressure is recorded as 
two numbers written as a ratio where the top number is the systolic blood 
pressure (SBP) and the bottom is the diastolic blood pressure (DBP). Systolic 
blood pressure is recorded when the first heartbeat is detected after releasing the 
cuff and represents the pressure in the arteries when the heart muscle contracts. 
Diastolic blood pressure is the number recorded when the last heartbeat is 
detected after releasing the cuff and represents pressure in the arteries when the 
heart relaxes. As per the AHA, the recommendation is for adults to maintain 
blood pressure less than 120/80 mmHg (systolic/diastolic) to avoid other 
complications associated with hypertension (6-8). Clinically, hypertension is 
diagnosed as blood pressure which is consistently greater than 140 mmHg 
systolic pressure and 90 mmHg diastolic pressure. Blood pressure between the 
healthy and hypertensive range is considered to be prehypertension. 
          There are two major determinants of blood pressure: the heart’s cardiac 
output (CO) and the total peripheral resistance (TPR). Cardiac output is defined 




either HR or SV is high, CO increases. Stroke volume is determined by the 
contractility of the heart and how much blood returns to the heart (venous return). 
Total peripheral resistance is the resistance on the arteries when the blood flows 
and can be regulated by a number of circulating factors, including angiotensin II 
(AngII), catecholamines, prostaglandins, direct innervation of specific receptors 
(α1 and β2), endothelin, adenosine, nitric oxide and also blood viscosity. Blood 
pressure is regulated by both divisions of the autonomic nervous system: the 




It has long been established that the renin-angiotensin system (RAS) plays a 
critical role in cardiovascular and renal homeostasis and has a central regulatory 
role on blood pressure maintenance (9). It is classically described as an 
endocrine system and regulates extracellular fluid and electrolyte balance 
thereby maintaining cardiovascular homeostasis in the body. The RAS comprises 
of several effector peptides that are formed through a series of enzymatic 
cleavages. The cascade is initiated when aspartyl-protease renin, secreted from 
the juxtaglomerular cells of the kidney cleaves the precursor globulin 
angiotensinogen (AGT) to form the decapeptide angiotensin 1-10 (commonly 
known as Ang I). Ang I is physiologically inactive but can be cleaved by the 
membrane-bound dipeptidyl carboxypeptidase, angiotensin converting enzyme 
(ACE), resulting in the formation of the octapeptide, AngII, the primary effector 
peptide of the RAS (10).  Additionally, AngI can be cleaved by angiotensin 




cleaved by ACE to form Ang-(1-7). Alternatively, ACE2 can also act upon AngII 
to generate Ang-(1-7).  
          AngII carries out its function by acting on two major G protein-coupled 
AngII receptor subtypes – AngII type 1 receptor (AT1R) and AngII type 2 receptor 
(AT2R). The AT1R has a wide tissue distribution with high expression in 
vasculature, kidney, adrenal gland, heart and some of the cardiovascular control 
brain regions (10-12). It is well recognized that the AT1R subtype mediates most 
of the well-known actions of AngII, including increased sympathetic output, 
vasoconstriction, release of vasopressin, norepinephrine (NE) and, aldosterone 
(13, 14). In addition the AngII-AT1R is also involved in sodium and water 
reabsorption in the kidneys, increase in heart rate, and stimulation of thirst and 
salt appetite(15) (Figure 1.1). Furthermore, recent studies have also 
demonstrated AngII-mediated activation of the immune system, particularly T cell 
and cytokine activation, which may act as a positive feedback loop in the 
development and maintenance of cardiovascular disease (16). The effects of 
AngII via the AT1R are mediated by complex signaling pathways involving 
phospholipids (phospholipase C (PLC), PLD, PLA2), induction of gene 
transcription (c-fos, c-jun, c-myc), activation of redox mechanisms such as 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and production 
of reactive oxygen species (ROS), and also activation of tyrosine kinases (Src, 
JAK-STAT, PI3K)(13, 17-19). In contrast, the AT2R which is highly expressed in 
fetal tissue, including fetal aorta, brain, adrenal medulla, kidney, and 




the actions of AT1R and does not have direct regulation on cardiovascular 
physiology (10, 20, 21). Furthermore, the AT2R can dimerize with the AT1R and 
interrupt the AngII-AT1R-mediated signaling mechanisms (21, 22). Most of the 
studies investigating the role of the different AngII receptor subtypes have been 
done by using specific receptor agonists and antagonists – for example, a 
selective agonist of the AT2R, compound 21, has shown beneficial effects on 
cardiovascular function and baroreflex sensitivity(23-25). On the other hand 
systemic administration of AT1R antagonist, such as losartan and irbesartan, 
lowers blood pressure and improves impaired baroreflex sensitivity in genetically 
hypertensive rats (26-29).  
          In contrast to the “hypertensive axis” of the RAS comprising ACE-AngII-
AT1R signaling, Ang-(1-7) binds to Mas receptor (MasR) to induce opposing 
effects to AngII-AT1R mechanisms. MasR is primarily expressed in brain and 
testis but also in kidney, heart and vessels, and its activation leads to 
vasodilation, decreased inflammation, reduction in sympathetic activity, 
antifibrotic, antihypertrophic and antithrombotic effects (12, 30, 31). The MasR can 
also heterodimerize with the AT1R and thereby antagonize it (32-34). The ACE2-
Ang-(1-7)-MasR is thereby considered as the “anti-hypertensive axis” of the RAS. 
Indeed, studies in the recent past have demonstrated the potential therapeutic 
effect of the ACE2-MasR axis on cardiovascular diseases including heart failure 
and hypertension (35). Moreover, the nonpeptide orally active MasR agonist AVE 
0991 has shown to preserve cardiac function and prevent end-organ damage in 




          Although AngII is considered as the primary effector peptide of the RAS, 
recent studies have identified some of the AngII metabolites as other active 
components of the system. Aminopeptidase A (APA) cleaves the N-terminal 
aspartyl residue of AngII resulting in the formation of Ang-(2-8), commonly 
referred to as Ang III. Ang III can be further metabolized into Ang-(3-8) (Ang IV) 
by aminopeptidase N (APN). Ang III displays comparable affinity to the AT1R and 
exerts similar actions as AngII such as aldosterone release and vasoconstriction 
(37, 38). APA inhibitors have also shown to attenuate central effects of AngII in 
AngII-mediated hypertension model (39). 
          Numerous studies done over the decades have illustrated the importance 
of different RAS components in blood pressure regulation and cardiovascular 
homeostasis by using specific pharmacological inhibitors as mentioned above. 
The pharmacological blockers were used either to inhibit the formation or actions 
of the key mediators of the RAS. In addition to β-blockers, some of the most 
widely used drugs in the treatment of hypertension and other cardiovascular 
diseases are the ones that inhibit ACE (ACEi) thereby limiting the formation of 






Figure 1.1- Renin-angiotensin system cascade. Abbreviations: ACE- 
angiotensin converting enzyme; ADH – anti-diuretic hormone (also known as 
vasopressin); AGT – angiotensinogen; ALD – aldosterone; Ang I – angiotensin I; 
AngII – angiotensin II; AT1R – angiotensin type 1 receptor; AT2R – angiotensin 
type 2 receptor; CAGE – chymostatin-sensitive angiotensin II-generating 
enzyme; MasR – mas receptor; NE – norepinephrine; NEP – neutral 
endopeptidase; PEP – prolylendopeptidase; PCP – prolylcarboxypeptidase; tPA 






Brain-angiotensinergic systems and hypertension 
 
 
The first identification of renin in the brain was made by Ganten et al. and Fisher-
Ferraro et al. (41, 42) and this was subsequently followed by identification of the 
existence of AngII-processing pathways in the central nervous system (CNS). 
The fact that AngII immunoreactivity is detected in the brain after nephrectomy 
(43, 44) suggests that the brain RAS is modulated independently of the peripheral 
RAS. Central injections of AngII in specific brain regions elicit profound 
cardiovascular and drinking response indicating the pivotal role of brain 
angiotensinergic mechanisms in cardiovascular control (45). Almost all of the 
RAS components have been identified in the CNS, including the enzymes that 
are involved in the generation of these effector molecules. For example, AGT, 
the primary precursor of AngII is widely distributed in the brain with the highest 
expression found in the hypothalamus, mainly the supraoptic nucleus (SON), 
paraventricular nucleus (PVN), and preoptic nucleus (46, 47). Interestingly, levels 
of renin, the enzyme that cleaves AGT into Ang I, is low in the brain and is 
detected in regions similar to AGT in addition to brain stem and cortical regions 
(48). However, recent studies have demonstrated the existence of prorenin and 
prorenin receptor (PRR) in important cardiovascular control brain nuclei (49). 
Non-proteolytic activation of prorenin by binding to the PRR can lead to 
increased generation of AngII independent of the renin pathway and neuron-
specific knock out of this receptor can attenuate blood pressure in a salt-sensitive 




biochemical and immunohistochemical studies have found ACE, the enzyme 
responsible for the conversion of Ang I to AngII in the basal ganglia, SON, PVN, 
nucleus tractus solitarius (NTS) and dorsal motor nucleus of the vagus (52, 53). 
These evidences thus suggest that AngII is produced in local tissues in the brain 
which is independent of the peripheral RAS. 
          In addition, systemic AngII can also act upon certain blood brain barrier 
(BBB) deficient brain nuclei known as circumventricular organs (CVOs) (54). 
These CVOs are present mainly bordering the third and fourth ventricles and are 
densely populated with fenestrated capillaries for high permeability (55). Among 
the CVOs, the subfornical organ (SFO), organum vasculosum of the lamina 
terminalis (OVLT) and area postrema (AP) (Figure 1.2) are the key 
cardiovascular control brain regions and express high levels of the AT1R (55, 56). 
The CVOs receive inputs from systemic baroreceptors and chemoreceptors and 
in turn send out neural projections to some of the downstream extensive neural 
network involved in maintaining various cardiovascular responses, vasopressin 
release, and autonomic responses (54, 57). More specifically, anatomical studies 
with anterograde tracing markers have identified projections from SFO in the 
forebrain to SON and PVN (54, 57, 58). Additionally, neurons from the 
parvocellular region of the PVN send axons to centers in the rostral ventrolateral 
medulla (RVLM) and intermediolateral cell column of the spinal cord, which are 
also important centers of sympathetic outflow and baroreceptor reflex regulation 
(54, 57, 58) The importance of CVOs in brain angiotensinergic signaling have 




neurons is greatly attenuated by electrolytic lesion of the SFO in rats (59-61). 
Lesioning the SFO also attenuates mean arterial pressure in an AngII-salt 
sensitive hypertension model (62). In addition, central injection of AngII directly 
into the SFO increases pressor, bradycardic and dipsogenic response (62, 63). 
Electrophysiological studies show that intravenous administration of AngII 
increases excitability of SFO neurons via an AT1R-mediated mechanism which 
inhibited transient outward potassium current and increased intracellular calcium 
(63-65).Furthermore, intracerebroventricular (ICV) infusion of losartan reduces 
AT1R mRNA and immunoreactivity in the SFO of heart failure animals (66). ICV 
infusion of losartan also reduces elevations in metabolic rate in a 
deoxycorticosterone acetate-salt (DOCA-Salt) hypertension model indicating the 
importance of brain angiotensinergic signaling in various animal models of 
hypertension (67). In addition to the SFO, destruction of the AP eliminates the 
pressor effect of AngII infusion into the vertebral arteries (68). Similar to the SFO, 
the central AngII-mediated dipsogenic and pressor effects can be blocked by 
lesion of the OVLT (68). 
          Selective overexpression of other components of the RAS, such as ACE2, 
in the brain can attenuate neurogenic hypertension by preventing decrease in 
spontaneous baroreflex sensitivity and parasympathetic tone (69, 70). ACE2 
overexpression in the brain also causes upregulation of the AT2 and MasR (69) 
thus shifting the balance between the “hypertensive” and the “anti-hypertensive” 
axis of the RAS. Ang III, another bioactive peptide of the RAS has similar affinity 




fluid and electrolyte balance (38, 71). Both AngII and Ang III in the brain are 
involved in increasing sympathetic nerve activity, inhibition of baroreflex 
sensitivity in the NTS and release arginine vasopressin (AVP) from the posterior 
pituitary. As such, studies by Marc et al. has identified inhibitors of APA, enzyme 
responsible for the generation of Ang III from AngII, to therapeutically target the 
brain RAS in hypertension (39). Together, these studies clearly demonstrate the 
significance of the brain angiotensinergic mechanisms in the regulation of neuro-
cardiovascular function and dysregulation in their signaling pathways can lead to 








Figure 1.2. Cardiovascular regulatory nuclei involved in brain 
angiotensinergic signaling mechanisms. Modified from Davisson and 





Angiotensin II intra-neuronal signaling mechanisms 
 
 
The AngII intra-neuronal signaling cascade involves a number of key mediators, 
including reactive oxygen species (ROS), protein kinases and phosphatases, ion 
channels, transcription factors, and matrix metalloproteinases (MMPs). The 
localization of the AngII receptor subtypes in the brain is quite different. For 
example, most of the AT1Rs are concentrated in the SFO, PVN, SON, and in the 
nuclei of the brainstem, whereas the AT2Rs are found in the thalamus, 
cerebellum, locus ceoruleus and particularly in the inferior olivary nucleus 
reflecting the different functional role of each of these receptor subtypes (13, 73). 
Numerous studies so far have well documented the AngII intracellular signaling 
mechanisms in the periphery (13, 74). In contrast, the neuronal signaling 
mechanisms mediated by AngII in the brain are still not fully understood. In the 
peripheral tissues and cells, AngII initiates a number of diverse signaling 
pathways via the AT1R, such as stimulation of phosphoinositide (PI) hydrolysis 
by coupling the AT1R to Gq or Gq-like protein. This is followed by generation of 
inositol (1,4,5)-triphosphatase (IP3), with subsequent increase in intracellular 
Ca2+ and diacylgylcerol (DAG)-mediated increase in protein kinase C (PKC) 
activity (17, 74). Interestingly, AT1R coupling to the Gi protein can inhibit adenylyl 
cyclase depending on the cell and type of tissue. AT1R activation by AngII can 
also stimulate Ras/Raf/mitogen activated protein (MAP) kinase and JAK 
(Janus/Kinase) STAT (signal transducers and activators of transcription) 




brain have demonstrated that a number of these AT1R-mediated AngII signaling 
occurs in the CNS. Activation of AT1Rs in the median eminence as well as in 
cultured neurons leads to a stimulation of PI hydrolysis causing IP3 generation 
and increases in [Ca]i and activation of PKC (13, 14, 75, 76). Furthermore 
increased concentration of [Ca]i activates downstream signaling molecules, such 
as calcium/calmodulin-dependent protein kinase II (CaMKII). The AngII-AT1R 
mediated PI hydrolysis is also observed in a neuroblastoma glial cell line (NG 
108-15). The Ras/Raf pathway and activation of MAP kinases by AngII by acting 
on the AT1R is also documented in cultured neurons. Increased MAP kinase 
activity mediates the known stimulatory effects of AngII on neuronal NE synthesis  
via the induction of Fos and Jun proteins (14, 77, 78). Furthermore, studies by 
Sumners and Raizada have demonstrated major short term effects of AngII on 
neuronal ion channel current and neuronal firing that is also mediated via the 
AT1R. For example, AT1R stimulation leads to an increase in total neuronal Ca2+ 
current (ICa) and also causes inhibition of delayed rectifier K
+ current (IKV) and the 
A type transient K+ (IA) current in primary neurons from rat hypothalamus and 
brain stem and also in a mouse catecholaminergic neuronal cell line (CATH.a 
neurons) (75, 79). These currents are the basis of neuronal action potentials and 
therefore, changes in Ca2+ and K+ ion channel current leads to an increase in 
neuronal firing frequency ultimately causing neuronal excitation. Involvement of 
signaling molecules, such as PKC and CaMKII have been investigated in the 
regulation of these ion channel currents by AngII by using specific inhibitors, 




Inhibition of either PKC or CaMKII attenuates the AngII-mediated reduction in IKV 
and the increase in neuronal firing frequency (80, 81). However, the precise 
mechanism by which AngII regulates PKC and CaMKII thereby modulating 
neuronal ion channels is not yet fully elucidated.  
          Similar to the AT1R, the AT2R-mediated intracellular signaling also 
modulates a variety of signaling molecules. In the heart, kidney, and cultured 
neurons, AT2R activation causes stimulation of phospholipase A2 (PLA2) activity 
(13). In neurons, this increase in PLA2 activity generates arachidonic acid which 
can then lead to regulation of neuronal ion channels (13). Several studies have 
also shown that in neurons, AngII by acting on the AT2R can activate 
serine/threonine phosphatase type 2A (PP2A) and in turn inhibit MAP kinase 
activity (78). Selective activation of the AT2R causes potentiation of neuronal IKV 
and IA, an effect opposing to the AT1R. AT2R does not seem to have any 
regulatory role on ICa in cultured neurons, but inhibits T-type Ca
2+ current in 
undifferentiated NG108-15 neuroblastoma x glioma cells (82). AngII-mediated 
AT2R activation thereby leads to a decrease in neuronal excitability. 
          To better understand AngII-intraneuronal signaling in the pathogenesis of 
neuro-cardiovascular disorders, several in vivo and in vitro experimental models 
have been established. Numerous studies have shown that acute stimulation of 
cultured neurons with AngII results in rapid increase in intracellular calcium, 
inhibition of outward potassium current (IKv), and an increase in neuronal firing 
(80, 81, 83, 84).In addition, chronic stimulation (i.e. hours to days) of AngII-




receptors, potassium channel proteins, and transcription factors (85, 86).  
Studies from these chronic AngII stimulation studies concluded that these events 
mimic the AngII neuronal signaling occurring in vivo in case of disease models, 
such as hypertension and heart failure where AngII levels are chronically 
elevated (87-89). However, one limitation of these in vitro studies has been the 
lack of evidence of chronic AngII stability in neuronal cell culture medium 









Figure 1.3. Angiotensin II-intraneuronal signaling mechanisms in central 
neurons. Abbreviations: AT1R – Angiotensin II type 1 receptor; ROS – reactive 
oxygen species; CaMKII – calcium/calmodulin-dependent protein kinase II; PKC 






Reactive oxygen species in the central nervous system 
 
Excessive activation of brain RAS or overproduction of AngII induces 
cardiovascular malfunctions (87). One of the most promising concepts that 
emerged during the last decade is AngII-mediated generation of reactive oxygen 
species (ROS) and activation of redox-dependent signaling cascades in the brain 
(84, 90). ROS are species of oxygen produced by all aerobic cells and are in a 
highly reactive state than molecular oxygen. Although they are best known for 
their role in host defense mechanisms (91, 92), ample evidences demonstrate 
ROS, primarily superoxide (O2
-) and hydrogen peroxide (H2O2) as key signaling 
molecules following stimulation of various plasma membrane receptors (93-95). 
Imbalance between ROS production and the ability of different scavenging 
systems to detoxify the reactive intermediates plays a critical role in neural 
mechanism of hypertension and heart failure (89, 96, 97). In the cells, ROS are 
mainly generated from incomplete reduction of molecular oxygen through 
enzymatic reactions involving NADPH oxidase (NOX) (98, 99) and xanthine 
oxidase (95, 100, 101), mitochondrial electron transport chain (ETC) (102-104), 
uncoupling of nitric oxide synthases (105), and through cyclo-oxygenases, 
lipoxygenases, or cytochrome P450 reductases (95, 106).  In the vasculature, 
Griendling and colleagues were the first to demonstrate that AngII activates NOX 
via the AT1R and this activation causes increase in intracellular O2
- formation 
which can lead to endothelial dysfunction and the pathogenesis of AngII-induced 





H2O2 from two major sources – NOX and the mitochondrial ETC. Additionally, 
activated proinflammatory cytokines can also mediate AngII-induced ROS 
production in the brain (56, 109). Accumulating evidence suggests that AngII 
activates AT1R in neurons of major cardiovascular control brain regions, such as 
the SFO, PVN and RVLM resulting in increased ROS levels which contribute to 
the increase in neuronal activation and subsequent stimulation of the 
sympathetic nervous system (97, 109). In addition, AngII reduces activities of 
Complexes I, II and III of the mitochondrial ETC, causing a suppression of 
electron transfer capacity between the complexes thus leading to electron 
leakage and generating increased O2
- and H2O2 (103). Importantly, the 
vasopressor, bradycardic and dipsogenic responses by intracerebroventricular 
(ICV) injection of AngII is mediated, at least in part, by O2
- in CVOs, such as the 
SFO (110). In the SFO, AngII leads to the increased production of O2
- and 
removing O2
- by specific antioxidants in the SFO abolishes the cardiovascular 
and dipsogenic responses to central AngII (90). The primary scavenger of O2
- is 
the superoxide dismutase (SOD). SOD catalyzes the dismutation of O2
- to H2O2 
and oxygen and is endogenously expressed as three different proteins: 1) 
copper/zinc SOD (CuZnSOD or SOD1), which is primarily localized in the 
cytoplasm, but also present in the mitochondria and nucleus; 2) manganese SOD 
(MnSOD or SOD2), which is strictly localized in mitochondrial matrix; and 3) 
extracellular SOD (ecSOD or SOD3), which is found extracellular. Adenovirus-
mediated overexpression of CuZnSOD in the SFO also prevents hypertension in 




mediating the full vasopressor effects of brain AngII in the SFO has been 
illustrated (111, 112) by using adenoviral vectors encoding small interfering RNA 
to selectively silence NOX2 and NOX4, the two NOX isoforms in the brain. 
Interestingly, silencing NOX2 alone and not NOX4, significantly attenuates the 
central AngII-induced drinking responses. The differential role of these two NOX 
enzymes in mediating the central AngII responses can be due to their different 
subcellular localizations in neurons. For example, NOX2 resides primarily in the 
plasma membrane, although it has not been fully elucidated in central neurons 
(113, 114). In contrast, recent study from our lab has demonstrated NOX4 to be 
localized in the mitochondria in CATH.a neurons (115). Furthermore, an important 
downstream cellular mechanism induced by O2
- is the influx of intracellular Ca2+ 
as seen in neuroblastoma Neuro 2A cells, which can be inhibited by adenoviral-
mediated expression of a dominant –negative isoform of Ras-related C3 
botulinum toxin substrate 1 (Rac1) (AdN17Rac1), a major component of NOX 
complex formation and activation (84). In addition, few studies suggest that ROS 
derived from NOX enhances nerve traffic in the SFO-PVN axis (116). Notably, 
Erdos et al have shown that ICV injection of AngII increases O2
- production both 
in the SFO and PVN and this increase in O2
-is attenuated by a NADPH oxidase 
inhibitor, apocynin (117). Importantly, the increase in AT1R and ACE mRNA in the 
PVN by ICV infusion of aldosterone is blocked by concomitant infusion of tempol, 
an SOD mimetic (118). Furthermore, in a model of 2-kidney-1-clip (2K1C) 
hypertension, the large increases in cardiac sympathetic activity, baseline renal 




AngII into the PVN is abolished by pretreatment with tempol or apocynin (119). 
Microinjection of tempol into the PVN also reduces high blood pressure and 
sympathetic activity of renovascular hypertensive rats (120, 121). Gene 
expression of NOX subunits, such as p47phox and gp91phox as well as AT1Rs 
is also increased in the PVN of those rats (121-123). Recent studies by Braga and 
colleagues have shown that overexpression of CuZnSOD into the PVN prevents 
the elevation of O2
- and the hypertensive response in the 2K1C hypertension 
model (122). Similar to the SFO and the PVN, the RVLM has also been 
recognized as one of the important brain sites for the accumulation of AngII-
induced O2
- and its impact on hypertension (124, 125). The RVLM receives inputs 
from the SFO and PVN forming the so-called SFO-PVN-RVLM pathway and 
contains bulbospinal neurons that are major inputs to the preganglionic neurons 
of the sympathetic nervous system (116, 126-128). It is densely populated with the 
AT1R (129) and pharmacological blockade of the AT1R attenuates the pressor 
response induced by AngII-microinjected into the RVLM of rabbits (130). In a slow 
pressor AngII hypertension model as well as in a 2K1C model, increased levels 
of O2
- have been demonstrated in the RVLM along with an increase in 
sympathetic nerve activity and overexpression of CuZnSOD specifically in the 
RVLM attenuates both the accumulation of O2
- and the sympathoexcitation (120, 
121, 124). In SHRs the MnSOD levels in the RVLM are found to be decreased 
(96). The AT1R mRNA expression as well as the NADPH oxidase subunits is 
increased in the RVLM of 2K1C rats (120, 124). Injection of tempol into the RVLM 




in 2K1C hypertensive rats (120). Additionally, overexpression of MnSOD in the 
RVLM inhibits the cardiovascular responses to AngII microinjected into the RVLM 
and also reduces sympathoexcitation and hypertension in SHRs. These studies 
therefore implicate the importance of ROS in the brain in different models of 
hypertension (131). 
          Several studies suggesting the role of brain ROS in mediating the 
pathogenesis of cardiovascular disorders has been done by using specific ROS 
scavengers, such as SOD. In addition to neurons in the brain, AngII can also 
cause O2
- generation from NOX enzymes in microglial cells (132, 133). Recent 
studies have also put forward a feed forward mechanism between NOX and 
mitochondria and the idea of a ROS-induced-ROS mechanism (134, 135). These 
studies suggest that AngII activates NOX leading to increases in intracellular 
Ca2+ concentration which can then be taken up by the mitochondria thus 
generating mitochondrial ROS. Indeed studies showing that knockdown of the 
p22phox subunit of NOX attenuates the AngII-induced O2
- and H2O2 production 
in the mitochondrial fractions isolated from the RVLM (103).  
           One of the major targets of ROS are ion channels and numerous 
evidences support the hypothesis that AngII-induced sympathoexcitation is 
mediated, atleast in part, by redox modulation of ion channels. The two important 
ion channels that play crucial role in action potential generation and neuronal 
excitability and can also be regulated by ROS, either directly or indirectly, are the 
Ca2+ and K+ channels (79). Evidence from both in vivo and in vitro studies 




ROS derived from NOX enzymes (84, 136)as well as mitochondrial sources (83). 
These studies also suggest a potential role of PKC and CaMKII in the regulation 
of these channels. Importantly inhibiting PKC and CaMKII by calphostin C and 
KN-93 respectively (80) in primary neurons cultured from rat hypothalamus and 
brainstem and scavenging superoxide by either CuZnSOD or MnSOD abolishes 
the AngII-mediated reduction in neuronal K+ current (83). Another class of protein 
kinases that are known to be redox-regulated and important in cardiovascular 
pathogenesis is the MAPK family of proteins. In the brain, redox activation of 
MAPK is involved in the AngII-mediated hypertension and heart failure (137, 
138). It is well recognized that in the RVLM, AngII via the AT1R-dependent 
activation of PKC-NOX-ROS signaling cascade triggers the activation of MAPKs, 
particularly p38MAPK and extracellular signal-regulated kinase (ERK) (139, 140). 
The activation of p38MAPK pathway in turn mediates the short-term pressor 
response of AngII by potentiating the glutamatergic neurotransmission in the 
RVLM (139). On the other hand, activation of ERK results in the long-term 
pressor response to AngII by upregulating the AT1R mRNA expression (141). 
The AngII-ROS-p38MAPK/ERK pathway in the RVLM is also implicated in the 
hypertensive phenotype in stroke-prone SHRs (142). In rats with CHF, AngII 
triggers the activation of ERK and c-Jun N terminal kinase (JNK) via ROS which 
contributes to the upregulation of AT1R and sympathoexcitation (143, 144). 
Furthermore, it has been reported in mouse CATH.a neurons, the AngII-
mediated inhibition of voltage-gated K+ channel expression is dependent on the 




protein kinases, such as Akt and Rho are also thought to be redox-sensitive and 
are active players in the pathogenesis of cardiovascular disorders (145-147). 
These studies confirm the role of ROS as key intermediates in AngII intra-
neuronal signaling and establish O2
- as a sympatho-excitatory molecule in the 
brain involved in the cardiovascular complications association with hypertension 
and heart failure. 
          However, although O2
- seem to be the major ROS molecule in AngII-redox 
signaling mechanisms, evidences also point out a potential role of H2O2 in some 
of the cardiovascular effects mediated by AngII. For example, in stroke-prone 
SHR, administration of catalase, the H2O2 scavenging enzyme, into the RVLM 
reduces the elevated levels of ROS (131). Catalase expression is also found to 
be low in the RVLM of SHRs and overexpression of catalase results in prolonged 
hypotension (96). In contrast, the H2O2 generated by dismutation of O2
- by 
CuZnSOD in the PVN does not play a role in the manifestation of 
sympathoexcitation associated with myocardial infarction-induced heart failure 
(148). Since catalase is primarily present in the peroxisomes and is not 
responsible for reducing H2O2 levels in different subcellular compartments, 
therefore, additional studies with other H2O2 removing enzymes, such as 
glutathione peroxidase (GPx) and peroxiredoxins (Prx) are required to confirm 











Elevated levels of ROS contribute to the adverse outcomes of many 
cardiovascular pathogenesis, including atherosclerosis, hypertension, heart 
failure, diabetes, cardiac hypertrophy and myocardial infarction (106, 149, 150). 
Increased production of oxidants, reduced nitric oxide (NO) bioavailability and 
decreased antioxidant defense mechanisms in specific organs are involved in 
these diseases. In many of these pathological models, in addition to ROS, 
excessive generation of reactive nitrogen species (RNS) is also involved thus 
leading to increased oxidative and nitrosative stress (151, 152). These excess 
oxidants not only affect cellular components, such as membrane lipids and 
nucleic acids (153, 154) but can also act as second messengers leading to post-
translational modifications (PTMs) of proteins thus altering cellular homeostasis. 
Different amino acids that make up a protein differ greatly in their susceptibility to 
get oxidized; however, the two most common PTMs of proteins occur in their 
sulfur-containing amino acids – cysteine and methionine (155, 156). Inside the 
cell, the cytoplasm is in a highly reducing environment and the protein cysteines 
are maintained in their thiol (-SH) or thiolate (-S-) state. This reducing 
environment is mainly due to the presence of the most abundant low-molecular-
weight thiol buffer glutathione (GSH). GSH is a cysteine-containing tripeptide 
(glutamate-cysteine-glycine) and is present in millimolar concentrations inside the 




pathways to remove any disulfide bond formation. These include the ubiquitous 
disulfide reductase, thioredoxin (Trx), which reduces oxidized protein substrates 
by using electrons derived from NADPH via its reactivating enzyme, thioredoxin 
reductase (TR), and glutaredoxin (Grx), which is reduced by GSH, which in turn 
is reduced by NADPH-dependent glutathione reductase (GR) (157, 159). 
However, under oxidative and/or nitrosative stress conditions the cysteine thiol 
groups of proteins are particularly susceptible to oxidation by ROS/RNS and 
other electrophilic molecules. The protein thiols not only function in normal 
cellular signaling but can also undergo irreversible oxidation in aging and disease 
conditions thus changing protein function.  The reactivity of most protein thiols is 
determined by its pKa (the acid dissociation constant) and at intracellular pH 
protein thiols have a pKa of approximately 8.5 which makes them less reactive 
(156, 157, 160). However, under certain local charge environments protein thiols 
can have a lower pKa and may exist as thiolate anions (cysteine-S-) at 
physiological pH thus making them more susceptible to oxidation to ROS/RNS. 
One such product of H2O2 oxidation is sulfenic acid (RSOH), which is unstable 
and can undergo further oxidation to generate more stable derivatives, such as 
sulfinic acid (RSO2H) or sulfonic acid (RSO3H), or react with another thiol to yield 
inter- or intra-protein disulfides (PrSSPr, PrSSPr’) (157). Importantly, protein 
disulfides, nitrosothiols, sulfenic acid and, in some cases sulfinic acid are 
reversible thus providing a mechanism of cell signaling regulation by reversible 
changes in protein function (160, 161). On the other hand, oxidation of sulfinic acid 




degraded or re-synthesized to restore their normal cellular levels and protect 
against oxidative damage (161). Additionally, cysteine residues can also be 
modified by RNS, such as NO to yield an S-nitrosothiol (R-SNO), and by 
peroxynitrite (ONOO-) to form S-nitrothiol (R-SNO2) (158, 162). As compelling 
evidences suggest the importance of regulation of protein function by thiol 
modifications, there have been tremendous efforts to develop methods to 
determine which proteins, and which amino acid residues within them are most 
reactive and also detect the specific thiol modifications. So far, mass 
spectrometry and proteomics approaches along with other free thiol labeling 
techniques are being utilized to accurately identify thiol modifications (163, 164).   
          The other sulfur-containing naturally occurring amino acid which is 
sensitive to oxidation is methionine. Due to the chiral nature of the sulfur atom in 
methionine, both free and protein-based methionine residues can undergo 
oxidation by ROS to form a mixture of two diastereomers, methionine-S-sulfoxide 
and methionine-R-sulfoxide (165). In the presence of a strong oxidant met 
sulfoxide can be further oxidized to methionine sulfone (MetO2) which can lead 
to many pathophysiological consequences (166). Similar to cysteine, oxidation of 
methionine can also lead to significant alterations of protein structure and 
function. As a means to counteract the methionine oxidation, methionine 
sulfoxide reductases (Msrs) have evolved as a reductase system in most 
organisms, including anaerobic organisms (167). Interestingly, in order to have a 
complete reduction of both methionine-(R,S)-sulfoxide residues in proteins two 




reduction of met-S-sulfoxide while MsrB acts only on met-R-sulfoxide (167-169). 
MsrA reduces both free and protein-based met sulfoxide and can also reduce 
other methyl sulfoxide compounds, such as dimethyl sulfoxide and sulindac (170). 
In contrast, MsrB has a very low activity towards free met sulfoxide and only acts 
efficiently on peptidyl met sulfoxide (170). In mammals, a single MsrA gene 
encodes for the MsrA protein and contains a mitochondrial signal peptide at the 
N-terminus. However, subcellular localization studies in rat and mouse have 
shown MsrAs are also present in the cytosol. The MsrB proteins are found in 
different cellular compartments and is encoded by three MsrB genes (B1-B3). 
The different subcellular localizations of MsrA and MsrB suggest that the met 
sulfoxide reduction system is maintained in different compartments of the 
mammalian cell to protect against met oxidation (165, 167). 
           Several studies have investigated the role of cysteine and met oxidation in 
target molecules in different experimental systems. For example, reversible 
oxidation of a specific cysteine residue in the amino-terminus of the voltage-
dependent K+ channel (Kv1.4) channel (171) or its associated β subunits (172) 
has shown to modulate the N-type inactivation of this channel.  In the brain, 
glutamate and H+ sensitivity of the NMDA receptors is also regulated by 
oxidation of two cysteine residues in NR1 subunits (173). In addition to ion 
channels, a number of protein kinases, phosphatases and transcription factors 
are also modulated by ROS and/or RNS. One such example is the redox 
regulation of different receptor tyrosine kinases (RTKs) that play an important 




binding. Once activated by ligand binding, the RTKs can relay its signal through 
downstream non-receptor kinases to mediate several biological processes (174). 
Finkel and colleagues in their landmark study have showed that the platelet-
derived growth factor (PDGF)-induced H2O2 production has downstream effects 
on global tyrosine phosphorylation, activation of MAPK pathways, DNA synthesis 
and chemotaxis (175). The other RTK, epidermal growth factor (EGF) also 
induced increase in ROS levels upon receptor binding (176). Further, inhibition of 
ROS production blocked the tyrosine signaling triggered by these RTKs 
stimulation. In addition, apoptosis signaling kinase 1, PKC, protein kinase A 
(PKA) has also been shown to be regulated by redox-based mechanisms in 
different signaling pathways (174, 177).  
          Redox sensitivity of protein phosphatases, particularly the protein tyrosine 
phosphatases (PTPs) such as PTP1B, low molecular weight PTP (LMW-PTP), 
SH2 domain containing PTPs (SHP-1 and SHP-2) has been well described (178). 
The pKa of the catalytic site cysteine of many PTPs is around 6, which makes 
them extremely reactive and forms thiolate anions at physiological pH. This 
reactive thiol group not only makes them highly susceptible to oxidation but is 
also essential for the catalytic mechanism of these PTPs (178).  The 
serine/threonine protein phosphatases, such as protein phosphatase 2A (PP2A), 
has also been shown to be regulated by H2O2 and glutathionylation (179, 180) and 
disulfide cross-linking of the catalytic subunit of PP2A with other proteins in the 
brain along with the formation of an intramolecular disulfide bond within PP2A 










Figure 1.4. Thiol-based oxidation of cysteine residues: role of reactive 













The family of multifunctional calcium/calmodulin (Ca2+/CaM)-dependent protein 
kinases (CaMKs) including CaMKI, CaMKII and CaMKIV modulate many of the 
cellular responses to Ca2+. These downstream effector molecules translate and 
co-ordinate the dynamic second messenger, Ca2+, into appropriate cellular 
responses by a highly specific and reversible phosphorylation of a number of 
substrate proteins in their serine or threonine residues. This family of protein 
kinases has both common as well as unique features with respect to their 
structure, regulation and activation. The CaMKII is responsible for the coupling of 
Ca2+ increase to ion channel activation (181), gene transcription (182), 
neurotransmitter synthesis and release, cytoskeletal organization and apoptosis 
(183). It should be noted that different functions of CaMKII are mediated by a 
family of CaMKII isoforms derived from four closely related yet distinct genes (α, 
β, γ and δ). CaMKII is highly enriched in the brain with the brain specific α (50 
kDa) and β (60 kDa) isoform constituting upto 2% of the total protein in the 
hippocampus of rodents and upto 1% of the total protein in the forebrain itself. 
Furthermore, in forebrain homogenates 19-37 µM concentration of CaMKIIα has 
been estimated in the cytosol. CaMKIIδ and γ isoforms are abundantly expressed 
throughout the body with the δ isoform predominantly found in the heart.  Purified 
brain CaMKII has a molecular weight of approximately 460000 – 654000 Da and 




have been identified from rat forebrain. The CaMKII is a multi-subunit 
holoenzyme containing three key domains: the association domain, which directs 
multimeric assembly, the regulatory domain, which controls enzyme activation 
and autoinhibition, and the catalytic domain, which is responsible for the kinase 
function of CaMKII.  Under resting conditions CaMKII is maintained in an 
autoinhibited state by the autoregulatory domain that acts as a pseudosubstrate, 
preventing the binding of substrates to the catalytic domain. The binding of 
Ca2+/CaM induces a conformational change in CaMKII that relieves the 
autoinhibitory effect of the regulatory domain and exposes the substrate binding 
site, thus activating the enzyme. One of the common features of all the CaMKII 
isoforms is the presence of autophosphorylation sites within the autoregulatory 
region, which is Thr286 in CaMKIIα (Thr 287 in β, γ and δ isoforms). In the 
sustained presence of Ca2+/CaM, intersubunit autophosphorylation in these 
threonine residues results in Ca2+/CaM-independent CaMKII activity by 
preventing the reassociation of the kinase domain with the autoinhibitory domain 
(181). The autophosphorylated CaMKII can then be dephosphorylated by either 
protein phosphatase 1 (PP1) or PP2A (184-186) to return to the inactive state. The 
molecular switch between the Ca2+-dependent and Ca2+-independent CaMKII 
activation is critical for the transformation of a transient Ca2+ stimulus into 
sustained physiological or disease-causing activity. 
          Recent studies have shown that the AngII-mediated pathological 
responses in the heart involves a second Ca2+/CaM independent activity of 




have shown that oxidation of a paired methionine residue (M281/282) in the 
cardiomyocyte isoform of CaMKII (CaMKIIδ) is a downstream signal for AngII 
and ischemic stress response in the heart and inhibition of CaMKII protects the 
heart against AngII-mediated apoptosis and other pathological myocardial 
responses (181, 187). They demonstrated that exposure of purified CaMKIIδ to 
H2O2 after pretreatment with Ca
2+/CaM yielded persistent CaMKII activation even 
in the presence of EGTA suggesting that Ca2+/CaM binding is required for the 
initial exposure of the key segment of CaMKII for oxidation as seen with 
autophosphorylation and that oxidation is able to maintain sustained CaMKII 
activity even without Ca2+/CaM binding. Mutation of M281/282 to valine 
completely abolished the H2O2 dependent activation of CaMKIIδ. Since, the 
paired met residue is conserved in all three isoforms of CaMKII except CaMKIIα 
(188) (CaMKIIα has a cysteine residue for the first methionine of the pair in 
position 280), they also generated a M281C mutant of CaMKIIδ and also purified 
CaMKIIα. Both purified CaMKIIα and M281C mutant CaMKIIδ were activated by 
H2O2 indicating the importance of cysteine in ROS-dependent CaMKII activation. 
In addition, heart sections of mice treated with AngII showed increased CaMKII 
oxidation whereas mice lacking a critical subunit of NADPH oxidase (p47-/-) did 
not show the AngII-mediated increase in CaMKII oxidation (181, 187).  
Interestingly, mice knockout for Msr A (MsrA-/-) had increased CaMKII oxidation 
and apoptosis with AngII and ischemia along with increased mortality, greater left 
ventricular dilation, and reduced in vivo mechanical function after myocardial 




has been implicated in excitotoxic neuronal cell death (189). The results from that 
study show that specific S-nitrosylation of C280/289 generated autonomous 
activation of CaMKII independent of Ca2+/CaM binding and mutation of either site 
protected from NO-induced neuronal cell death. The redox sensitivity of CaMKII 
has also been illustrated in studies where large increases in cytosolic Ca2+ 
causes mitochondrial O2
- generation and upregulation of CaMKII in hippocampal 
neurons (190). Activation of CaMKII by this mitochondrial-induced O2
- is also 
mediated atleast in part by oxidative suppression of protein phosphatases that 
dephosphorylate CaMKII. Studies by Yin et al. have also showed that in CATH.a 
neurons AngII increases CaMKII phosphorylation, causing CaMKII activation, 
with a significant increase observed after 5 minutes of AngII stimulation (83). 
However, neurons, which were transduced with AdMnSOD (adenovirus 
overexpressing manganese superoxide dismutase) had reduced CaMKII 
phosphorylation, indicating that superoxide is involved in mediating AngII-
induced CaMKII activation in central neurons. These studies therefore illustrate 
the importance of redox regulation of CaMKII in physiological and pathological 
responses. 
Specific Aims and Hypotheses 
 
 
Based on the detailed discussion of the background, the following specific aims 
and hypotheses were developed to (1) determine the chronic stability of 
exogenous AngII in neuronal cell culture media and (2) examine the redox-




channels and increased blood pressure in AngII-dependent neurogenic 
hypertension. 
          The overall hypothesis is that mutation of specific redox-sensitive cysteine 
and methionine residues in CaMKIIα will prevent the AngII-mediated inhibition of 
neuronal K+ current and also the hypertensive response induced by central or 
subcutaneous infusion of AngII. Additionally, a single exogenous administration 
of AngII is rapidly metabolized in neuronal cell culture media and in order to 
mimic chronic elevated levels of AngII in certain disease models repeated AngII 
administration in media is needed. The experiments proposed herein provide 
new information on how CaMKIIα can be modified by ROS and exaggerate the 
AngII signaling in neurons. More specifically, the results of the study provide 
important new insight on the specific residues of CaMKIIα that can be oxidatively 
modified and can thus be utilized for the treatment of neuro-cardiovascular 
pathologies such as hypertension. 
 
Specific Aim 1: Determine the stability of exogenous AngII in neuronal 
culture media.  
This aim tests the hypothesis that AngII is rapidly metabolized in neuronal cell 
culture media following exogenous AngII stimulation. The levels of AngII and its 
metabolites, Ang III, Ang IV and Ang-(1-7), were measured in the media from 
cultured CATH.a neurons by liquid chromatography-tandem mass spectrometry. 
A single administration of AngII (100 nM) was used to treat CATH.a neurons and 




metabolites. AngII levels were also measured after repeated administration of 
fresh exogenous AngII every 3 hours for up to 24 hours. 
Specific Aim 2: Determine the functional relevance of overexpressing wild-
type CaMKIIα in the regulation of AngII-modulated neuronal K+ channel and 
the AngII-induced hypertensive response.  
This specific aim tests the hypothesis that adenovirus-mediated overexpression 
of wt-CaMKIIα (wt-AdCaMKIIα) in CATH.a neurons potentiates the AngII-
mediated inhibition of K+ current. In addition, we hypothesize that wt-CaMKIIα 
overexpression in the brain exaggerates the AngII-induced increase in blood 
pressure in mice. A series of in vivo and in vitro experiments were performed to 
test the hypothesis. Molecular biology techniques, including polymerase chain 
reaction (PCR) and cloning was utilized to generate the major neuronal isoform 
of CaMKII (CaMKIIα) adenovirus. The overexpression of wt-CaMKIIα in CATH.a 
neurons was assessed by measuring the mRNA and protein expression using 
real time PCR and Western blot analysis respectively. Whole-cell patch clamp 
technique was utilized to measure changes in baseline K+ channel current and 
following AngII stimulation in non-infected, control adenoviral, AdEmpty and wt-
AdCaMKIIα transduced CATH.a neurons. Furthermore, wt-AdCaMKIIα and 
adenovirus overexpressing green fluorescent protein (AdGFP) was injected 
intracerebroventricularly (ICV) in mice by ICV cannulas and blood pressure and 
heart rate responses were measured following either central acute or chronic 
subcutaneous AngII infusion. Blood pressure and heart rate responses were 




Specific Aim 3: Determine the functional relevance of oxidative post-
translational modifications of CaMKIIα in regulating neuronal ion channel 
current and in mediating AngII hypertension in mice. 
Based on the previous studies discussed, both cysteine and methionine residues 
present in the autoregulatory domain of CaMKII has been shown to be 
oxidatively modified. This aim will therefore test the hypothesis that mutation of 
specific redox-sensitive cysteine and methionine residues in CaMKIIα will 
attenuate the AngII-mediated inhibition of neuronal K+ current and also the AngII-
induced rise in blood pressure. A mutant CaMKIIα adenovirus (mut-AdCaMKIIα) 
was generated with C280A and M281V substitutions and was transduced in 
CATH.a neurons to record K+ current at baseline and after 5 minutes of AngII 
superfusion. To investigate the effect of mut-CaMKIIα in the brain on the AngII-
mediated hypertensive response, mice were injected with ICV mut-CaMKIIα 
adenovirus and blood pressure and heart rate responses were recorded after 







Figure 1.5. Schematic representation of overall hypothesis. AngII increases 
superoxide which in turn leads to enhanced CaMKII oxidation and activation. 
Activated CaMKII subsequently decreases neuronal potassium current and 
increases neuronal firing frequency. Activation of central neurons leads to an 






Chapter II: Exogenous Angiotensin II is Rapidly Metabolized in 






Activation of the renin-angiotensin system along with increased levels of AngII in 
the brain has been associated with the development and maintenance of various 
forms of experimental and genetic models of hypertension (87, 88, 191, 192). In 
the brain, AngII can act on specific nuclei that are important in autonomic control 
of cardiovascular function. These brain regions include the subfornical organ 
(SFO), paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM) and 
nucleus tractus solitaries (NTS). AngII has been shown to increase neuronal 
firing in these brain areas, thus leading to the deleterious sympathoexcitation 
commonly associated with neuro-cardiovascular diseases (193-196). In central 
neurons, AngII mediates most of its actions by acting primarily on its type 1 
receptor (AT1R). For example, AngII stimulation of the AT1R in the above 
mentioned cardiovascular control brain regions and others contributes to 
vasopressin secretion, thirst and salt appetite, and baroreflex modulation (197-
199). In addition, AngII can also activate its type 2 receptor (AT2R) on central 
neurons, which often results in opposing responses compared to AT1R activation, 
reflecting the different physiological and pathophysiological roles of AngII 





            Considering the importance of AngII intra-neuronal signaling in the 
pathogenesis of neuro-cardiovascular diseases including hypertension and heart 
failure, numerous studies have been devoted to better understand the precise 
signaling pathways involved in an attempt to identify new therapeutic targets for 
these diseases. However, there are significant technical challenges in studying 
AngII-induced intra-neuronal signaling in vivo in animal models of hypertension 
and heart failure such as: 1) limited number of neurons within a specific 
cardiovascular control brain region of interest to perform a particular assay; 2) 
separating intra-neuronal signaling events from other pathways activated in 
neighboring cells including glia and endothelial cells; and 3) separating the 
signaling mechanisms of other peptides and hormones associated with these 
diseases from those directly induced by AngII. To circumvent these challenges, 
neuronal cell culture models have been frequently utilized to examine the specific 
intra-neuronal signaling pathways induced by AngII. Such studies have clearly 
identified important roles for calcium, reactive oxygen species, kinases, and 
transcription factors in the AngII intra-neuronal signaling pathway (80, 84, 86, 
90).  
          Nevertheless, there are also limitations in using neuronal cell culture 
models to recapitulate the AngII intra-neuronal signaling events occurring in vivo 
such as: 1) neuronal cells are often immortalized and/or isolated from a tumor; 2) 
cells are usually cultured in a hyperoxic environment (i.e. 21% oxygen) as 
compared to their in vivo environment (1-4% oxygen); and 3) the lack of 




cultured neurons that would normally occur in vivo. A fourth limitation in using 
neuronal cell culture models as it specifically relates to understanding AngII intra-
neuronal signaling is the lack of evidence indicating the stability of exogenous 
AngII in neuronal cell culture media. Many studies have examined intra-neuronal 
responses, such as changes in mRNA levels and protein expression, 1-48 hours 
after a single administration of exogenous AngII into the neuronal cell culture 
media (200-202). Data from these studies are often interpreted to indicate that the 
observed changes are also occurring in neurons of various hypertensive and 
heart failure models in which circulating and/or brain levels of AngII are 
chronically elevated(203, 204). However, it remains unclear if a single treatment 
of exogenous AngII given to neurons in culture results in a chronic elevation of 
AngII levels in the media.  
          In the current study, we tested the hypothesis that exogenous AngII is 
rapidly metabolized in neuronal cell culture medium and thus fails to remain 
chronically elevated following a single exogenous administration. We utilized a 
mouse catecholaminergic neuronal cell line, CATH.a neurons, which express 
both AT1R and AT2R. CATH.a neurons have commonly been used by our group 
and others to study AngII intra-neuronal signaling pathways (80, 85, 115). 
Previous studies have shown that deletion of the AT1R from catecholaminergic 
neurons delays the onset of AngII-dependent hypertension and also reduces the 
maximal blood pressure response (205). In addition, catecholaminergic neurons, 
such as C1 neurons in the RVLM, play an important role in AngII-induced 




the AngII-mediated rise in blood pressure (206). Using liquid chromatography-
tandem mass spectrometry, we measured levels of AngII and its metabolites, Ang 
III, Ang IV, and Ang-1-7, in CATH.a neuronal cell culture media after 
administration of exogenous AngII. Herein, we report that exogenous AngII is 
rapidly metabolized in CATH.a neuron media with levels returning to near 
baseline after 3 hours of administration. Further, AngII levels in CATH.a neuron 
media can be significantly and chronically elevated for at least 24 hours with the 




Neuronal cell culture 
 
 
Mouse catecholaminergic CATH.a neurons (American Type Culture Collection 
(ATCC), Manassas, VA) were cultured in RPMI 1640 medium (Gibco/Invitrogen, 
Grand Island, NY) supplemented with 8% normal horse serum (NHS) (ATCC), 
4% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin-
streptomycin (Gibco) at 37 ºC with 5% carbon dioxide (CO2) as recommended by 
ATCC. CATH.a neurons were differentiated for 6 - 8 days before experimentation 
by adding N6,2′-O-dibutyryladenosine 3′,5′ - cyclic monophosphate sodium salt 
(dbcAMP, 1 mM, Sigma-Aldrich, St. Louis, MO) to the culture medium as 
previously described (207). Neurons were serum starved for 18-24 hours before 
treatment or experimentation. CATH.a neurons are derived from tyrosine 




carrying the SV40 T-antigen oncogene. The CATH.a neuronal culture expresses 
tyrosine hydroxylase and dopamine β hydroxylase enzymes thereby producing 
norepinephrine and dopamine respectively. It should be noted that CATH.a 
neurons express both AT1 and AngII type 2 receptor (AT2R) and have been 
widely used by various groups to study AngII intra-neuronal signaling 
mechanisms (196, 207, 208). 




CATH.a neuronal culture medium was collected after incubation (15 minutes – 24 
hours) with AngII (100 nM). 13C- and 15N-labeled (Leu, + 7 amu) AngII (H-AngII, 
Anaspec, Fremont, CA) was added to the media samples at a concentration of 
18.2 nM. Proteins were precipitated by addition of 6 volumes of cold neat 
acetone, typically 50 µl of sample and 300 µl of acetone and stored at -35 ºC for 
1 hour. Then, the samples were centrifuged at 4 ºC for 15 minutes at 15,000 x 
g. Thereafter, the supernatants were removed and the acetone/water was 
removed by SpeedVac concentration for 2 - 3 hours at room temperature. The 
pellet was re-dissolved into 50 µl of 0.1% formic acid, vortexed, and 
centrifuged. The samples were loaded onto V-shaped polyethylene vials (Agilent, 
Santa Clara, CA) that were previously soaked with 0.1% w/v BSA and dried. The 
LC-MS/MS method was developed and used for the samples using an Agilent 
LC1200 HPLC system (Agilent, Santa Clara, CA) connected to an  ABSciex 
QTrap4000 (ABSciex, Framingham, MA) operating in multiple reaction monitoring 




conditions were Temperature, 500 oC, ionization potential, 5500 V, GS1= 50, 
GS2= 25, curtain gas= 30. The transitions monitored and ionization parameters 
are shown in Table I. Transitions numbered 1,3,5,8 and 9 were used for 
quantitation while the remaining ones were used for confirmation of peak 
assignment. Column chromatography was performed via a 2.1 x 50 mm Kinetex 
C-18 300 Å (Phenomenex, Torrance, CA) at a flow rate of 250 µl/min with a 
mobile phase gradient from 98% A (0.1% formic acid in LC-water) to 98% B 
(0.1% formic acid in acetonitrile) over 20 min, with additional holding at 98% B for 
2 mins and re-equilibration at 98% A for 10 min. Transitions were monitored with 
an acquisition time of 100 msec/MRM in non-scheduled mode. The data were 
analyzed using Analyst Ver 1.4.2. AngII levels were quantified using H-AngII as a 
standard. The other angiotensin peptides (Ang III, Ang IV, and Ang-1-7) were 
quantified by comparison to an external calibration curve of the unlabeled 
commercially available peptides, and H-AngII was used as a surrogate to correct 
for concentration loss of the peptides during sample preparation. The recoveries 
of the spiked H-AngII were equal to or higher than 80% for the analytical method. 
Individual samples were injected in triplicate and the average angiotensin peptide 
concentrations and standard error are reported. All reagents used for LC-MS/MS 
analysis were of Mass Spectrometry Grade and all unlabeled angiotensin peptide 




 All data are expressed as mean ± standard error of the mean (SEM) and were 




Newman-Keuls correction for multiple comparisons. Statistical analyses were 
performed using GraphPad Prism 5.0 statistical and graphical software. 
Differences were considered significant at p<0.05. 
Results 
 
Utilizing liquid chromatography – tandem mass spectrometry to detect 
angiotensin peptides 
 
AngII is generated from angiotensin converting enzyme (ACE) cleaving 
angiotensin I, which is produced by renin-induced cleavage of angiotensinogen. 
Although AngII is considered to be the primary effector peptide of the renin-
angiotensin system, AngII can be further metabolized to other angiotensin 
peptides which have been shown to contribute to cardiovascular function (39, 207, 
209). For example, AngII can be cleaved by angiotensin converting enzyme 2 
(ACE2) (210-212) to form Ang-1-7 or by aminopeptidase A to form Ang III, which is 
further metabolized by aminopeptidase N to form Ang IV (Figure 2.1). Although 
the primary objective of this study was to examine the stability of exogenous 
AngII in neuronal cell culture media, it was also important to determine if 


























Figure 2.1. Schematic of the renin-angiotensin system. AngII is generated by 
angiotensin converting enzyme (ACE)-induced cleavage of angiotensin I. AngII is 
subsequently metabolized to Ang III and Ang-1-7 peptide via aminopeptidase A 
and angiotensin converting enzyme 2 (ACE 2), respectively. Ang III is further 






           As shown in the representative chromatogram (Figure 2.2), we were able 
to successfully separate and detect all four angiotensin peptides from a mixture 
containing the commercially available peptides ranging in concentration from 12-
16 nM. AngII is an octapeptide which under the conditions of the chromatography 
should accumulate in the +3 charged state due to the positive charges at the 
terminal amino group as well as the Arg and His side chains. Upon loss of the C-
terminus Phe, rendering Ang-1-7, the peptide is much less hydrophobic and thus 
binds less strongly to the C-18 side chains of the HPLC column particles. Since 
Phe is more hydrophobic than Asp, removal of Asp instead of Phe from AngII 
makes the Ang III peptide less hydrophobic than AngII but more than Ang-1-7. 
Therefore, Ang III elutes between Ang-1-7 and AngII (Figure 2.2). The 
hexapeptide Ang IV is generated from the removal of the N-terminus positive side 
chain Arg from Ang III, while keeping the hydrophobic residues Ile and Phe. As a 
result of Ang IV being the most hydrophobic, it has the strongest binding and thus 
appears as the last peak in the chromatogram (Figure 2.2). To accurately 
quantify the concentration of these peptides in our subsequent studies using 
media samples from the CATH.a neuronal culture, we utilized 13C- and 15N-









Figure 2.2: Angiotensin peptides detected by liquid chromatography-
tandem mass spectrometry. Representative chromatogram showing the 
detection of individual angiotensin peptides (AngII, Ang III, Ang IV, and Ang-1-7) 
in a mixture of the commercially available peptides in a concentration ranging 
from 12-16 nM. 13C- and 15N-labeled AngII (H-AngII) was also added to the 
mixture and used to quantify absolute amounts of the angiotensin peptides in the 
CATH.a neuronal cell culture media samples analyzed in subsequent 






Exogenous AngII is rapidly metabolized in CATH.a neuronal cell culture 
media 
 
Levels of AngII, Ang III, Ang IV, and Ang-1-7, were measured in CATH.a neuronal 
cell culture media 15 min – 24 hours after a single administration of exogenous 
AngII (100 nM) into the media. As expected, AngII was significantly elevated in 
the media 15 minutes after administration as compared to media collected 
immediately prior to treatment (Figure 2.3A). Levels of AngII rapidly decreased 
over time until 3 hours-post administration when levels of AngII in the media were 
significantly lower compared to the 15 min time-point and not significantly 
different than baseline levels. AngII remained low, that is, it was undetectable 6 
and 24 hours after administration. Interestingly, levels of Ang III (Figure 2.3B) and 
Ang-1-7 (Figure 2.3D) modestly, but significantly, increased 15-60 minutes after 
exogenous AngII administration. In contrast, levels of Ang IV remained 
unchanged compared to baseline levels (Figure 2.3C). It should be noted that we 
specifically selected the AngII concentration of 100 nM for these studies because 
we wanted to replicate, as best we could, the experimental conditions used in 
other published studies(80, 83) designed to examine the AngII-induced acute and 
chronic responses in cultured neurons. For example, we previously used 100 nM 
AngII to study AngII-mediated intra-neuronal signaling in CATH.a neurons and 
have shown that at this concentration AngII-induced Nox4-generated 




K+ current (83, 115). Furthermore, Sun et al. have reported that 100 nM AngII 
rapidly inhibits the delayed rectifier K+ current and increases neuronal firing rate 
in primary neurons isolated from the brain (80, 81). Additional studies examining 
more long-term changes (i.e. hours to days) in the expression of various proteins, 
including AngII receptors, potassium channels, and transcription factors, also 























Figure 2.3: Exogenous AngII levels rapidly decrease within 3 hours in 
CATH.a neuronal cell culture media. Levels of AngII (A), Ang III (B), Ang IV (C), 
and Ang-1-7 (D) in CATH.a neuronal cell culture media following a single 
administration of exogenous AngII (100 nM) as measured by liquid 
chromatography-tandem mass spectrometry. Absolute concentrations were 
calculated against the standard 13C- and 15N-labeled AngII peptide. n = 3 
separate experiments performed in triplicate. *p < 0.05 vs. 0min AngII; #p < 0.05 






Exogenous AngII is stable in neuronal cell culture media in the absence of 
CATH.a neurons 
 
The rapid decrease in exogenous AngII levels in media collected from CATH.a 
neurons may suggest that the peptide is degraded by the media itself. To 
examine this possibility, AngII (100 nM) was added to the media in the absence 
of CATH.a neurons and samples were collected 15 min – 24 hours later (Figure 
2.4). AngII levels remained significantly elevated at all time-points with 
concentrations near the starting concentration of 100 nM (Figure 4A). In contrast, 
levels of Ang III, Ang IV, and Ang-1-7 were not significantly different than baseline 








Figure 2.4: AngII is stable in neuronal cell culture media in the absence of 
CATH.a neurons. Levels of AngII (A), Ang III (B), Ang IV (C) and Ang-1-7 (D) in 
cell culture media without CATH.a neurons following a single administration of 
exogenous AngII (100 nM) as detected by liquid chromatography and tandem 
mass spectrometry. Absolute concentrations were calculated against the 
standard 13C- and 15N-labeled AngII peptide. n = 3 separate experiments 






Replenishing CATH.a neuronal cell culture media every 3 hours with fresh 
exogenous AngII results in chronic elevated levels 
 
 Finally, to determine if levels of AngII could be chronically elevated in CATH.a 
neuronal cell culture media, we administered fresh exogenous AngII (100 nM) 
every 3 hours and measured AngII for up to 24 hours. As shown in Figure 2.5, 
AngII levels remained similarly and significantly elevated (63-72 nM) at each 




















Figure 2.5: Repeated administration of exogenous AngII every 3 hours 
maintains a chronic elevated level of AngII in CATH.a neuronal cell culture 
media. Levels of AngII in CATH.a neuronal cell culture media following repeated 
administration of exogenous AngII (100 nM) into the media every 3 hours for 6, 9, 
12, 15, 21, and 24 hours. Absolute concentrations were calculated against the 
standard 13C- and 15N-labeled AngII peptide. n = 3 separate experiments 








The pathogenesis of various cardiovascular disorders, such as hypertension and 
chronic heart failure, involves dysregulation of the brain angiotensinergic system 
(73, 89, 214). Understanding the precise intra-neuronal signaling mechanism(s) 
driving this dysregulation may lead to the identification of new targets for which 
novel therapeutics can be developed. As such, numerous studies have focused 
on examining the intra-neuronal signaling molecules and proteins mediating the 
physiological and pathophysiological responses of AngII (14, 97, 109). Many of 
these studies have relied on neuronal cell culture models to demonstrate a role 
for signaling intermediates, such as calcium, ROS, kinases, and transcription 
factors in mediating the AngII-induced response (80, 84, 86, 90). However, 
relating these in vitro observations to in vivo AngII-dependent cardiovascular 
diseases, such as hypertension and chronic heart failure, where circulating and 
central levels of AngII are chronically elevated (203, 204) is problematic as the 
stability of exogenously administered AngII in neuronal cell culture media is 
unknown. In the current study, we examined the stability of exogenous AngII in 
the culture media of an AngII-sensitive neuronal cell culture model, CATH.a 
neurons, that has commonly been utilized to study AngII intra-neuronal signaling 
(80, 85, 115). Herein, we report that levels of exogenous AngII are diminished to 
near baseline levels within 3 hours of treatment, and that media should be 
replenished with fresh AngII every 3 hours to maintain chronically elevated levels 
of the peptide in this neuronal cell culture model.  




rapid increase in intracellular calcium (84), inhibition of outward potassium 
current (IKv) (80, 83), and an increase in neuronal firing (81). Chronic stimulation 
(i.e. hours to days) of AngII-sensitive cultured neurons leads to alterations in the 
expression of angiotensin receptors (200, 202), potassium channel proteins (85), 
and transcription factors(201). However, in most, if not all, of these chronic 
stimulation studies a single administration of exogenous AngII was given to 
neurons in culture. This begs the questions of whether AngII remains stable in 
the culture media for hours or days to continuously activate its receptors to 
mediate these changes in protein expression or if these changes are a result of 
the immediate stimulation of AngII receptors followed by prolonged intra-neuronal 
signaling events. The more long term changes might be a result of downstream 
intermediate signaling events and not a direct effect of AngII binding to its 
receptors on these neurons. With these questions unanswered, it is difficult to 
compare results obtained from these types of in vitro studies with data obtained 
from in vivo cardiovascular disease models in which AngII receptors are likely 
constantly activated due to the chronically elevated levels of AngII. Our new data 
presented herein indicates that levels of exogenously administered AngII in 
neuronal cell culture media are decreased to near baseline levels within 3 hours; 
thus, suggesting that changes in protein expression at later time points are due 
to prolonged intra-neuronal signaling events rather than continuous activation of 
AngII receptors. In fact, we observed that within 15 minutes of treating cells with 
100 nM AngII only 53±4 nM AngII remained in the media, and by 3 hours post-




AngII is metabolized in the media to Ang III and Ang-1-7, as the concentration of 
these two peptides increased 15 minutes after AngII treatment. We speculate 
that most of the AngII lost within the first 15 minutes of treatment is bound to the 
AngII receptors and internalized via receptor-mediated endocytosis. In support of 
this hypothesis, previous studies using aortic smooth muscle cells have 
demonstrated that after AngII binds to its receptor the complex is internalized 
with a half-time of less than 2 minutes (215). In addition, previous reports indicate 
a functional role for internalized AngII after it has bound to the AT1R and the 
complex has been endocytose (216). For example, the complete AT1R-induced 
activation of mitogen‐activated protein kinase (MAPK) is believed to be 
dependent on internalization (217). Furthermore, nuclear membrane-associated 
angiotensin receptors have been identified (208, 218) and may be stimulated by 
internalized AngII and/or by AngII generated via an intracellular renin-angiotensin 
system (67).   
  After observing the rapid decrease in exogenously administered AngII in 
the media of our neuronal cell culture model, we questioned whether this was 
cell-mediated or non-specific degradation of AngII in the media. To address this 
question, we measured levels of AngII in culture media in the absence of CATH.a 
neurons after a single exogenous administration of 100 nM AngII, and found that 
AngII is relatively stable in the media. More specifically, the concentration of AngII 
at all time-points measured (15 minutes to 24 hours) was approximately 80 nM or 
greater. Taken together with our results in the presence of CATH.a neurons, 




CATH.a neurons is mostly cell-dependent with the AngII being metabolized to 
Ang III and Ang-1-7, or binding to its receptors, along with some non-specific 
degradation of the peptide. As such, it is likely that the stability of exogenous 
AngII in cultured media will be drastically different between various cells types. 
That is, the expression levels of aminopeptidase A, which cleaves AngII to Ang 
III, ACE2, which cleaves AngII to Ang-1-7, and/or AngII receptors in a particular 
cell type will influence the stability of exogenous AngII in the respective media. 
Although we did not observe a change in Ang IV in the current study with CATH.a 
neurons, it is tempting to speculate that the amount of aminopeptidase N, which 
cleaves Ang III to Ang IV, expressed by a particular cell line will also contribute to 
the levels of these angiotensin peptides in culture media. Furthermore, it is 
possible that the stability of AngII in culture media may be experimentally 
manipulated by the exogenous administration of aminopeptidase inhibitors, ACE2 
inhibitors, and/or AngII receptor antagonists.  
 In conclusion, our results demonstrate that a single exogenous 
administration of AngII to CATH.a neurons in culture does not result in chronically 
elevated levels of AngII in the media. As such, we sought to determine if multiple 
and sequential administration would keep AngII levels elevated chronically. Our 
data show that giving fresh AngII (100 nM) every 3 hours to cultured CATH.a 
neurons does indeed keep levels of AngII in the media significantly elevated for 
at least 24 hours. We believe cell culture models with chronically elevated levels 
of AngII are the ideal in vitro models that one should utilize to study the precise 




diseases associated with systemic and/or local chronically elevated levels of 
AngII, including hypertension and chronic heart failure. We posit that keeping 
levels of AngII chronically elevated in cell culture models will change the cellular 
response induced by AngII compared to the response induced by a single 
administration. Alternatively, it is possible that AngII levels may not need to be 
chronically elevated in cell culture media to induce long-term effects as the initial 
stimulation of AngII receptors may activate intracellular signaling pathways that 
lead to chronic changes in the expression of AngII receptors, ion channel 
proteins, and transcription factors. To address these hypotheses, our laboratory 
is currently investigating changes in AngII-dependent intracellular signaling 
events in CATH.a neurons exposed to single versus repeated administration of 
AngII. More specifically, we are examining changes in AngII receptor expression, 
levels of ROS and antioxidants, intracellular calcium concentration, activation of 
transcription factors, and expression of ion channels. Importantly, we are 
comparing any changes in response to single or repeated administration of AngII 
to those that we observe in cardiovascular control brain nuclei (e.g. SFO, PVN, 
RVLM) collected from animal models in which AngII is known to be chronically 
elevated in the brain, including hypertensive and chronic heart failure models. 
We believe these, and other, future studies will provide further insight into the 
importance of establishing cell culture models with chronically elevated levels of 





Chapter III: Overexpression of wild-type calcium/calmodulin-dependent 





As described in the previous chapter, we have shown that exogenous AngII 
added to neuronal cells in culture is metabolized within 3 hours; whereas, at 15 
minutes post-treatment levels of AngII remain significantly elevated in the culture 
media. In the current chapter, my overall objective was to determine the 
contribution of CaMKII in AngII intra-neuronal signaling. Considering the 
observations discussed in the previous chapter, I decided to focus on the acute 
(i.e. 5-10 minutes) AngII-induced physiological response, which in cultured 
neurons is a change in ion channel activity. In fact, AngII has been shown to 
regulate neuronal ion channels, including the voltage-gated potassium and 
calcium channels (80, 84). However, the signaling mechanism(s) driving this 
response has yet to be precisely identified.  
            Several studies by Sun and colleagues have shown that AngII can 
regulate neuronal K+ current (IKV) thereby increasing neuronal firing rate and 
causing neuronal activation (80, 81). More specifically, they showed  that AngII 
inhibits IKV, particularly the delayed rectifier K
+ current and this results in an 
increased frequency of neuronal firing both in primary neurons isolated from rat 
hypothalamus and brain stem, and in a mouse catecholaminergic neuronal cell 
line (CATH.a neurons)(80, 81). Additionally, they showed that the AngII-induced 




AngII type 1 receptor (AT1R) antagonist losartan (79). Interestingly, these studies 
also demonstrated that the AngII-mediated reduction in IKV and increased 
neuronal firing rate involves signaling intermediates, such as phospholipase C 
(PLC), protein kinase C (PKC), and calcium/calmodulin-dependent protein kinase 
II (CaMKII) (80, 81, 219). These studies elucidated that inhibition of PLC, PKC or 
CaMKII using U73122, calphostin C or KN-93, respectively, attenuates AngII-
mediated reduction of IKV and increased neuronal firing suggesting a critical role 
for these signaling proteins in AngII-induced neuronal responses. Although these 
data suggest a role for CaMKII in AngII signaling in central neurons, the non-
specificity of the CaMKII inhibitor, KN-93, used in these previous studies brings 
into question the precise CaMKII isoform involved. As such, we set out to 
specifically investigate the contribution of the predominant neuronal isoform of 
CaMKII (CaMKIIα) in mediating the AngII-induced regulation of neuronal ion 
channels. 
             Calcium/calmodulin-dependent protein kinase II (CaMKII) is a 
multifunctional enzyme which couples increases in intracellular Ca2+ to regulation 
of ion channels. Under resting conditions CaMKII remains inactive, but upon 
binding with Ca2+/CaM the autoinhibitory domain of CaMKII is relieved from the 
kinase domain and undergoes inter-subunit autophosphorylation of a threonine 
residue (T286 in neuronal CaMKIIα isoform). Autophosphorylation in the 
regulatory domain causes CaMKII activation enabling it to phosphorylate several 
target proteins.  Several protein phosphatases, like protein phosphatase 2A 




leading to its inactive resting state (184-186). The switch between Ca2+/CaM-
dependent and Ca2+/CaM-independent sustained CaMKII activation is therefore 
important in determining the role of CaMKII in physiological and pathological 
conditions. Interestingly, recent studies have shown that the AngII-mediated 
pathological responses in the heart involves a second Ca2+/CaM independent 
activity of CaMKII under elevated ROS conditions. These studies have identified 
the CaMKIIδ isoform, which is primarily expressed in cardiomyocytes, as a 
downstream target of AngII in case of myocardial infarction and ischemic stress 
responses during heart diseases (181, 187, 220). Elevated levels of ROS in 
presence of AngII can cause oxidation of a paired methionine residue 
(M281/282) in CaMKIIδ, which thereby leads to sustained CaMKIIδ activation 
independent of Ca2+/CaM and mediates AngII-stimulated apoptosis in the heart. 
Additionally, the study also found that substituting the first methionine (M281) of 
CaMKIIδ with a cysteine residue, which is similar to the CaMKIIα isoform, also 
sustains CaMKIIδ activation under oxidant conditions. These data provide insight 
into the redox sensitivity of CaMKIIα which has a cysteine/methionine 
(C280/M281) instead of the paired methionine residues.  
            Studies in our lab have previously shown that in CATH.a neurons AngII 
rapidly activates CaMKII by increasing CaMKII phosphorylation with a significant 
increase observed after 5 minutes of AngII stimulation (83). However, in that 
study, neurons which were transduced with AdMnSOD (adenovirus 
overexpressing manganese superoxide dismutase) had reduced CaMKII 




CaMKII phosphorylation. Additionally, scavenging superoxide in CATH.a neurons 
also attenuated the AngII-mediated reduction in IKV. In an attempt to identify 
specific voltage-gated K+ channels involved in AngII-mediated increased 
neuronal firing, Gao et al., have showed that expression of Kv4.3 is 
downregulated in presence of AngII stimulation in CATH.a neurons (85).However, 
the precise mechanism(s) by which AngII regulates CaMKIIα thereby modulating 
neuronal ion channels is not fully understood. 
          Furthermore, as discussed in Chapter I, AngII in the brain acts on specific 
nuclei that are important in autonomic control of cardiovascular function, 
including the paraventricular nucleus (PVN), rostral ventrolateral medulla 
(RVLM), and nucleus tractus solitarius (NTS) (193, 195, 196).  AngII can also 
activate neurons of circumventricular organs, such as the subfornical organ 
(SFO) and lead to sympathoexcitation, which contributes to hypertensive 
symptoms, such as increased vasoconstriction, enhanced salt and water 
reabsorption, increased heart rate, and activation of T-lymphocytes and 
inflammatory cytokines (194, 197-199). Past studies have also demonstrated that 
scavenging superoxide with adenoviral-mediated overexpression of copper-zinc 
superoxide dismutase (AdCuZnSOD) in the SFO attenuates blood pressure in an 
AngII-infused hypertensive animal model (90). However, the role of downstream 
effector molecules, such as CaMKIIα in the brain in mediating the AngII-induced 
hypertensive response in animal model is unclear. 
  In the present study we tested the hypothesis that adenovirus-mediated 




AdCaMKIIα) exacerbates the AngII-mediated inhibition of neuronal K+ current 
and potentiates the AngII-induced hypertensive response in mice. We show that 
wt-CaMKIIα overexpression indeed intensifies the reduction of IKV in AngII-
stimulated CATH.a neurons and also enhances the AngII-induced pressor 
response in mice. Overall, this study implicates CaMKIIα as a key mechanistic 
player in AngII-signaling in central neurons. 
Experimental Methods 
 
CATH.a neuronal cell culture 
 
For detailed descriptions of mouse CATH.a neuronal cell culture and 
differentiation, see experimental methods in Chapter II. During adenovirus 
transduction cells were treated with serum free media with dbcAMP for 18-24 
hours following which virus was removed and media replaced with serum full 
media with fresh dbcAMP. 
Adenoviral vector construction 
 
Replication-deficient recombinant adenovirus (Ad5-CMV) encoding mouse wild-
type calcium/calmodulin-dependent protein kinase IIα (wt-AdCaMKIIα) was 
generated. CaMKIIα plasmid (Origene) was amplified by conventional 
Polymerase Chain Reaction (PCR) using the HotStart PCR Master Mix (Qiagen, 
Venlo, Limburg) and the following forward and reverse primers: forward 5’- GAA 
TTC ATG GCT ACC ATC ACC TGC ACC C – 3’; reverse 5’ – GGA TCC TCA ATG 
CGG CAG GAC GGA - 3’. The PCR product was then run on a 1% agarose gel, 




PCR clone jet kit (Thermo Scientific) was used to clone CaMKIIα insert in various 
vector to insert ratios to determine the optimum ratio for cloning. It was then 
transformed into DH5 alpha bacteria and grown overnight onto ampicillin treated 
plates at 37oc in a bacterial incubator. Bacterial colonies were picked and grown 
in luria broth (LB) media overnight by shaking. PureLink Quick Plasmid DNA 
Miniprep Kits (Invitrogen, Grand Island, NY) were used to isolate CaMKIIα 
plasmid DNA as per manufacturer’s instructions. Following quantification of the 
DNA using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, 
MA) 1µg DNA was digested with EcoR1 and BaMH1 (New England Biolabs, 
Ipswich, MA) restriction enzymes and then run on a 1% agarose gel to confirm 
the presence of the correct insert. The plasmid samples were then sent off to the 
UNMC Gene Sequencing Core. Once the wt-CaMKIIα sequence was confirmed it 
was then cloned into an expression plasmid, transformed into DH5 alpha 
bacteria, DNA isolated, digested using restriction enzymes and again sent to the 
UNMC Gene sequencing core to confirm the presence of correct wt-CaMKIIα 
sequence in the expression plasmid. Adenoviral vectors were then constructed, 
purified and provided by the University of Iowa Gene Vector Core as previously 
described (83, 221). 
RNA extraction, cDNA and quantitative real-time RT-PCR 
 
 
To confirm the overexpression of wt-CaMKIIα at the transcriptional level and to 
evaluate the effect of wt-CaMKIIα overexpression on other CaMKII isoforms, total 
RNA was extracted from differentiated CATH.a neurons using the Trizol method 




concentration was determined spectrophotometrically by using a Nanodrop 2000 
Spectrophotometer (Thermo Scientific). 1 µg of each sample RNA was reverse 
transcribed and cDNA was generated by Taqman reverse transcription kit 
(Applied Biosystems, Foster City, CA). SYBR green (Applied Biosystems) 
quantitative real-time PCR was performed with generated cDNA with primers 
specific to the coding sequence of CaMKIIα, CaMKIIβ, CaMKIIδ, CaMKIIγ. 
Additional primers specific to voltage-dependent K+ channels such as KV2.1, KV2.2, 
KV4.2 and KV4.3 were also used. Primer sequences were as follows: CaMKIIα 
forward, 5’- TGA CAG CCT TTG AAC CAG AG - 3’; CaMKIIα reverse, 5’- CAA 
AAT AGA ATC GAT GAA AGT CCA - 3’; CaMKIIβ forward, 5’- GGA CAT CTG 
GGC ATG TGG - 3’; CaMKIIβ reverse, 5’- CAC TCA GGG GAT GGG AAA T -3'; 
CaMKIIδ forward, 5’- TCA ACC CTG CCA AAC GTA TC - 3’; CaMKIIδ reverse, 5’ 
– GAG GCA ACA GTA GAG CGT TGA - 3’; CaMKIIγ forward, 5’ – GCT CAA TGT 
CCA CTA TCA CTG C - 3’; CaMKIIγ reverse, 5’ – TCA CTC AGG CCC TCC AGA 
– 3’; Kv2.1 forward, 5’ – GGA GAA GCC CAA CTC ATC G - 3’; Kv2.1 reverse, 5’ 
– TGT TGA GTG ACA GGG CAA TG – 3’; Kv2.2 forward, 5’ – CCG GAG AAA 
CGG AAG AAA C - 3’; Kv2.2 reverse, 5’ – ATA GAC ACG ATG GCC AGG AT – 3’; 
Kv4.2 forward, 5’ – GCT TTG AGA CAC AGC ACC AC - 3’; Kv4.2 reverse, 5’ – 
TGT TCA TCG ACA AAC TCA TGG – 3’; Kv4.3 forward, 5’ – TGC CAC TGT GAT 
GTT TTA TGC - 3’; Kv4.3 reverse, 5’ – TCT TAG GCA CCA TGT CTC CA – 3’  
The PCR parameters were 95oc for 10 minutes, followed by 40 cycles of 95oc for 
15 seconds and 60oc for 1 minute. Thermal dissociation was used to determine 




amplification was selected and the cycle threshold (Ct) was determined. Levels 
of transcripts were then normalized to the 18S rRNA loading control and 
compared relative to the control sample using the ΔΔ Ct method. 
Western blot analysis 
 
 
To determine the optimal overexpression of CaMKIIα, CATH.a neurons were 
transduced with wt-AdCaMKIIα on day 3 of differentiation and Western blot 
analysis was performed to confirm CaMKIIα overexpression. Protein expression 
of total CaMKIIα, phosphorylated CaMKIIα (P-CaMKIIα) and actin was 
determined using standard Western blot analysis in whole cell lysates prepared 
from differentiated CATH.a neurons either non-transduced or transduced with 
control adenoviral vector, AdEmpty (10, 25 and 50 multiplicity of infection (MOI) , 
or wt-AdCaMKIIα (10, 25 and 50 MOI). Briefly, cells were harvested in phosphate 
buffer saline (PBS) containing protease inhibitor cocktail (Sigma-Aldrich) and 
phosphatase inhibitor (Thermo Scientific) and then sonicated. Cell lysates (25-30 
µg of protein per lane) were loaded onto 12.5% Bis-Tris gels, separated by SDS-
PAGE and transferred to a nitrocellulose membrane. Membranes were incubated 
at 4 ºC overnight with primary antibodies directed against CaMKIIα (1:1000 
dilution, abcam, Cambridge, UK) P-CaMKIIα (1:1000 dilution, abcam) and actin 
(1:1000 dilution, Sigma-Aldrich). After incubation with goat anti-rabbit horseradish 
peroxidase-conjugated secondary antibody (1:5000 dilution, Thermo Scientific) 
for two hours at room temperature, bands were visualized using the Pierce 
enhanced chemiluminescence detection system (Thermo Scientific, Rockford, 




Institutes of Health (NIH) ImageJ analysis software. Values were normalized to 
actin to correct for any variations in protein loading. 
Electrophysiological record of voltage-gated K+ currents 
 
 
Differentiated CATH.a neurons either non-transduced or transduced with 
AdEmpty (25MOI), or wt-AdCaMKIIα (25MOI) were used to measure K+ currents 
(IKV). IKV was recorded by the whole-cell configuration of the patch-clamp 
technique using an Axopatch 200-B patch-clamp amplifier (Axon Instruments, 
Inc, Union City, CA). Briefly, in the voltage-clamp experiments, resistance of the 
patch pipette was 4-6 MΩ when filled with the following solution (in mM): 130 
KCl, 2 MgCl2, 0.25 CaCl2, 5 EGTA, 1 Mg-ATP, 0.1 Tris-GTP, 10 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and 8 glucose, pH 7.2. 
The extracellular solution consisted of (in mM): 137 NaCl, 5.4 KCl, 1.35 CaCl2, 2 
MgCl2, 0.3 NaH2PO4, 10 HEPES, 10 sucrose, pH 7.4. To selectively record IKV, 
Na+ and Ca2+ channels were blocked by 0.5µM tetradotoxin (TTX, Sigma-Aldrich) 
and 0.3 mM CdCl2  (Sigma Aldrich), respectively. Current traces were sampled at 
10 kHz and filtered at 5 kHz. Holding potential was -80 mV and current-voltage (I-
V) relationship was elicited by 10 mV step increments to potentials between -80 
and +80 mV for 400 ms. The change of IKV with AngII was tested by superfusing 
CATH.a neurons with AngII (100 nM) for 5 minutes and repeating the voltage 
pulse regimen. To confirm the observed changes with AngII, IKV was recorded 
again after 15 minutes of washout. Cells that responded to AngII stimulation and 
then recovered with the washout were considered for data analysis. Current 




capacitance (Cm). The Cm of CATH.a neurons utilized in the study ranged from 
10-60 pF and was not significantly different between the groups. The pClamp 
10.2 program (Axon Instruments) was used for data acquisition and analysis. All 
experiments were carried out at room temperature. 
In vivo mouse studies 
 
 
All animal procedures were reviewed and approved by the University of 
Nebraska Medical Center Institutional Animal Care and Use Committee, and 
were performed in accordance with the Guidelines for the Care and Use of 
Experimental Animals of the American Physiological Society and the National 
Institutes of Health. Adult C57BL/6 male mice 7-8 weeks of age (20 - 26 g body 
weight) were acquired from Harlan laboratories (Indianapolis, IN) for the in vivo 
experiments. Mice were individually housed in temperature and humidity-
controlled cages at the University of Nebraska Medical Center animal facilities 
with a 12 hour light-dark cycle. Mice were provided standard chow and water ad 
libitum. At the end of each experiment mice were euthanized with intraperitoneal 
injection of pentobarbital (150 mg/kg). 
Implantation of radiotelemeters in mice 
 
 
For blood pressure recordings anesthetized mice were surgically instrumented 
with left carotid radiotelemeters (TA11PA-C10 catheter, Data Sciences 
International, St. Paul, MN).  Mice were anesthetized with 0.5-2.0% isofluorane 
and a ventral midline skin incision was made from the jaw to the sternum to 




carotid artery and the telemeter catheter was advanced so that the tip was 
positioned inside the thoracic aorta. The transmitter of the radiotelemeter was 
placed in a subcutaneous pouch in the right abdominal flank of each mouse. The 
neck incision was then closed with an interrupted suture using a prolene 
monofilament suture material (Ethicon, Inc). Topical bupivacaine (AAP 
Pharmaceuticals, LLC, India) was applied on the surgical site. For real-time 
measure of cardiovascular parameters, such as mean arterial pressure, systolic 
pressure, diastolic pressure, heart rate and pulse pressure, mice were placed on 
individual telemeter receivers after magnetically activating the radiotelemeters. 
Data were viewed using Dataquest Advanced Research Technology version 4.1 










Figure 3.1: Placement of radiotelemeter catheter in the intracarotid artery. 
Image from: www.ddah.org.uk/phenotyping-telemetry.htm 
Intracerebroventricular (ICV) cannula implantation in mice 
 
 
Anesthetized mice were strategically placed on a stereotaxic apparatus (World 
Precision Instruments) with the help of ear bars. A ventral midline incision was 




in the same horizontal plane. An anchoring screw was inserted into the right 
frontal bone slightly anterior to the coronal suture. The cannula (25 gauge, 
Plastic One, Roanoke, Virginia) was then placed 0.3 mm posterior and 1 mm 
lateral to the bregma and a hole was dilled following which the cannula was 
inserted into the hole 3.3 mm below the bregma and affixed to the skull with 
acrylic dental cement (Stoelting, Wood Dale, Illinois). A stylus, specifically fitted to 
the length of the cannula, was inserted into the cannula to maintain an 
unobstructed opening into the ICV system. Note that mice which received both 
radiotelemeter implantation and ICV cannula had their cannulas placed on the 
same day immediately following radiotelemetry surgery.  
 




 All ICV injections were made through a 33-gauge stainless steel injector 
connected to a Hamilton microsyringe via PE-10 tubing. For the acute studies, 
following 1 week of recovery from ICV cannula and radiotelemetry implantation 
surgery, the mice received a single acute ICV AngII (350 ng) injection. Blood 
pressure and heart rate responses were recorded in conscious freely, moving 
mice for 20 minutes after injection. 3 days of acute AngII response was recorded 
prior to injecting adenoviruses. Mice were injected with either ICV AdGFP or wt-
AdCaMKIIα (5x107 plaque forming units). Following adenovirus injection, 
baseline blood pressure was recorded for 3 days after which acute physiological 




immunohistochemistry studies, 7 days after adenovirus injection, mice were 
euthanized with intraperitoneal injection of fatal plus (40 mg/kg, Henry-Schrein, 
Inc., Melville, NY). Brains were removed and fixed in 4% paraformaldehyde in 0.1 
M phosphate buffer (PB) and then stored in 30% sucrose in PB overnight prior to 
sectioning. For the chronic AngII-induced hypertension studies ICV cannula-
instrumented mice received either AdGFP or wt-AdCaMKIIα adenovirus (5x107 











Figure 3.2: Intracerebroventricular cannula implantation for AngII and 
adenovirus injection to the subfornical organ. 
Modified from: Peterson et al. Hypertension. 2009 (111). 
 
Subcutaneous implantation of osmotic minipumps in mice 
 
 
For chronic AngII infusion studies mice were implanted 3 days post adenovirus 
injection with osmotic minipumps (Alzet, Durect Corporation, Cupertino, CA) 
subcutaneously to deliver either Ang II (400 ng·kg-1·min-1) or saline for 
approximately 3 weeks. It is to be noted that the dose of AngII was selected 




hypertension induces a gradual increase in blood pressure that mimics human 
essential hypertension (222, 223). The osmotic minipumps were primed at least 
for 12 hours in saline at 370c prior to implantation. On the day of surgery, mice 
were anesthetized (0.5 – 2.0% isoflurane) and the left flank was shaved.  A small 
horizontal incision was made in the left flank and a subcutaneous pocket was 
created to insert the osmotic minipumps. The incision was closed with an 
interrupted suture using a prolene monofilament suture (Ethicon, Inc.). Topical 









Figure 3.3: Timeline for acute central AngII-mediated pressor response 






Figure 3.4: Timeline for chronic subcutaneous AngII-mediated pressor 









To verify the overexpression of CaMKIIα in mouse brain tissues 
immunohistochemical staining was performed in brain sections 7 days post ICV 
adenovirus injections. 20 µm sections of the mouse brains were prepared using a 
cryostat (Leica CM3050S) and immunohistochemistry was carried out. Sections 
were first incubated for 1 hour with blocking buffer (10% NHS in 0.1 M PB) and 
then incubated at 4 ºC overnight with a rabbit primary antibody against CaMKIIα 
(1:200, abcam) and a rabbit P-CaMKIIα (1:200, abcam) prepared in 0.1 M PB 
containing 2% NHS and 0.3% Triton X-100. The sections were then washed in 
0.1 M PB and incubated with Alexa Fluor 598 secondary antibody (1:200, 
Invitrogen) at room temperature for 2 hours. Fluorescent images of the 
subfornical organ and ventricles were detected by confocal laser scanning 





All data are presented as means ± standard error of the mean (SEM). Data were 
analyzed by Student’s t-test for two group comparisons or by ANOVA with 
Newman Kewls post-hoc test. P-value less than 0.05 was considered statistically 
significant. Statistical analyses were performed using GraphPad Prism 5.0 







Adenoviral-mediated transduction of wt-CaMKIIα increases total and 
phosphorylated CaMKIIα protein in CATH.a neurons 
 
To confirm the adenovirus efficiency and overexpression of CaMKIIα, mouse 
CATH.a neurons were either non-transduced or transduced with control 
adenovirus, AdEmpty, or wt-AdCaMKIIα at 10, 25 and 50MOI on day 3 of 
differentiation. As compared to non-transduced or AdEmpty-transduced neurons, 
CATH.a neurons transduced with wt-AdCaMKIIα had a significant increase in 
total CaMKIIα protein levels at 25 and 50 MOI as detected by Western blot 
analysis (Figure 3.5A). This was accompanied by an increase in phosphorylated 
levels of CaMKIIα suggesting an increase in active CaMKIIα in CATH.a neurons 
at 25 and 50 MOI (Figure 3.5B). CaMKIIα mRNA overexpression was also 
confirmed by real-time quantitative PCR in differentiated CATH.a neurons. While 
transduction with wt-AdCaMKIIα resulted in a significant dose-dependent 
increase in CaMKIIα mRNA in CATH.a neurons, the other isoforms of CaMKII, 
such as CaMKIIβ, CaMKIIδ and CaMKIIγ did not change in between groups 
(Figure 3.5C). Kinase activity assay was utilized to measure CaMKII activity in 
AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI)-transduced CATH.a neurons. 
Neurons with wt-CaMKIIα overexpression had 3-fold higher activity as compared 
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Figure 3.5. Transduction of wt-CaMKIIα adenovirus causes significant 
upregulation of CaMKIIα expression and activity in CATH.a neurons. (A) 
Representative Western blot analysis of CATH.a neuronal cell lysates probed for 
primary antibody against total and phosphorylated CaMKIIα; Summary densitometry 
data of Western blot analysis showing levels of (B) CaMKIIα and (C) P-CaMKIIα in 
non-transduced, AdEmpty (10, 25 and 50 MOI)- and wt-AdCaMKIIα (10, 25 and 50 
MOI)-transduced neurons; Real-time RT-PCR data with primers specific for CaMKIIα 
(D), CaMKIIβ (E), and CaMKIIδ (F) genes normalized to 18s rRNA and expressed as 
fold control; (G) CaMKII activity in AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI)-
transduced neruons as measured by kinase activity assay and reported as fold 





Wild-type CaMKIIα overexpression potentiates AngII-mediated inhibition of 
K+ channel current in CATH.a neurons 
 
To investigate the effect of wt-CaMKIIα overexpression on the AngII-dependent 
changes in electrophysiological properties, voltage-gated K+ channel current (IKV) 
was measured in differentiated non-transduced, either AdEmpty or wt-
AdCaMKIIα-transduced CATH.a neurons. Whole-cell patch-clamp technique was 
used to record baseline IKV and IKV after 5 minutes of AngII (100 nM) superfusion.  
Compared to baseline, 5 minutes of AngII superfusion inhibited IKV by 20% in 
non-transduced and AdEmpty-transduced CATH.a neurons and this effect of 
AngII could be restored after AngII washout (Figure 3.6). Interestingly, AngII 
superfusion caused a significant reduction in IKV by approximately 37% in wt-
AdCaMKIIα-transduced CATH.a neurons. It is to be noted that AngII attenuated 
both transient K+ current (Ipeak) and the steady-state K
+ current (Iss) to a similar 
extent in CATH.a neurons as previously described (241). To confirm our finding 
that the AngII-induced reduction in IKV was mediated by CaMKII, CATH.a neurons 
were pretreated for 30 minutes with the CaMKII inhibitor, KN-93 (10 µM) and 
baseline IKV recordings were measured followed by 5 minutes of AngII 
superfusion and wash out. The AngII-mediated reduction in IKV was significantly 
abolished in presence of KN-93. These data indicate that wt-CaMKIIα 
overexpression enhances the AngII-induced inhibition of neuronal K+ channel 






















Figure 3.6. Wild-type CaMKIIα overexpression potentiates the AngII-
mediated inhibition of outward K+ current in CATH.a neurons. 
Representative traces of evoked K+ currents in CATH.a neurons superfused with 
vehicle or 100 nM AngII (A) and percent inhibition of outward K+ current following 
5 minutes of AngII (100 nM) superfusion pretreated for 30 minutes in the absence 
or presence of 10 µM KN 93 (B) in non-transduced, AdEmpty (25MOI) or wt-
AdCaMKIIα (25 MOI)-transduced CATH.a neurons (n = 7 biological replicates for 






Wild-type CaMKIIα overexpression upregulates mRNA expression of Kv 
channels in CATH.a neurons 
 
To determine the causal relationship between overexpression of wt-CaMKIIα and 
significant reduction in K+ current in CATH.a neurons, we sought to detect mRNA 
expression of specific voltage-dependent K+ channels which have previously 
been shown to be present in important autonomic regions of the brain and also 
involved in AngII-mediated signaling in neurons (85, 224). Quantitative real-time 
PCR was utilized with specific primers for individual Kv channel transcript to 
detect mRNA levels of Kv2.1, Kv2.2, Kv4.2 and Kv4.3. Interestingly, as compared to 
AdEmpty-transduced CATH.a neurons, transduction of wt-AdCaMKIIα modestly 
increased mRNA expression of the above mentioned KV channels in CATH.a 
neurons at baseline (Figure 3.7). These data indicate that overexpression of wt-
CaMKIIα leads to transcriptional upregulation of these voltage-dependent K+ 
channels which may act as a compensatory mechanism to counteract the 










Figure 3.7. Overexpression of wt-CaMKIIα modestly increase mRNA 
expression of voltage-dependent K+ channels in CATH.a neurons. 
Quantitative real-time PCR analysis showing (A) Kv2.1, (B) Kv2.2, (C) Kv4.2 and 
(D) Kv4.3 mRNA levels in AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI) 
transduced CATH.a neurons. n=3 biological replicates in all experimental groups. 






Overexpression of wt-CaMKIIα potentiates the central acute AngII-induced 
increase in mean arterial pressure 
 
Our in vitro studies suggest that overexpressing CaMKIIα in CATH.a neurons 
exacerbates the AngII-mediated reduction of neuronal K+ channel current. To 
determine the role of CaMKIIα overexpression in the brain on central actions of 
AngII in vivo, C57BL/6 male mice underwent radiotelemetry implantation and 
intracerebroventricular (ICV) cannula surgeries. Following a week’s recovery, 
blood pressure responses to ICV administered AngII (350 ng) were recorded in 
conscious mice. As seen in the representative recordings mice receiving acute 
ICV AngII had a characteristic significant increase in blood pressure as compared 
to their baseline blood pressure (Figure 3.8A). Interestingly, 3 days post 
adenovirus injection, the AngII-mediated rise in blood pressure was further 
potentiated in ICV AdCaMKIIα-injected (n = 9) mice as compared to AdGFP-
injected (n = 9) mice. The peak changes in mean arterial pressure following 
acute ICV AngII injections in AdCaMKIIα and AdGFP mice group are summarized 
in Figure 3.8B. In addition, the duration of the AngII-induced pressor response 
was also longer in CaMKIIα-overexpressed mice as compared to mice receiving 
AdGFP (Figure 3.8C). The duration of the AngII-mediated response was 
calculated from the start of the peak AngII-induced rise in blood pressure until the 

































Figure 3.8. Overexpression of wt-CaMKIIα in the brain potentiates the 
pressor response of central acute AngII. (A) Representative mean arterial 
pressure tracings and (B) summary data showing AngII-induced acute pressor 
response  in mice injected with ICV AngII (350 ng) both pre- and 3 days post-ICV 
injection of AdGFP or wt-CaMKIIα adenovirus. (C) Duration (in minutes) of the 
AngII-mediated rise in blood pressure in AdGFP and wt-AdCaMKIIα injected 





          To confirm efficient adenovirus-mediated overexpression of wt-CaMKIIα in 
the subfornical organ (SFO), an important cardiovascular regulatory brain 
nucleus, immunohistochemistry was performed on AdGFP and wt-AdCaMKIIα-
injected mice brain tissue sections 7 days post ICV adenovirus injections. As 
shown in the representative confocal microscopy images, the SFO of wt-
AdCaMKIIα injected mouse brains possessed higher levels of CaMKIIα 
fluorescence in comparison to AdGFP brain sections (Figure 3.9). Together, the 
data presented here strongly indicate that CaMKIIα in the brain is an important 









Figure 3.9.  Adenoviral-mediated overexpression of wt-CaMKIIα in the 
subfornical organ (SFO). Representative confocal microscopy images showing 
expression of (A) GFP, CaMKIIα and (B) GFP , P-CaMKIIα in SFO of mice 1 
week after intracerebroventricular (ICV) injection of AdGFP or wt-AdCaMKIIα. 
Coronal brain sections (20 µm) were stained for GFP (green), total and 
phosphorylated CaMKIIα (red). Double staining is shown in the merged (yellow) 





Adenovirus-mediated wt-CaMKIIα overexpression in the brain sensitizes 
mice to an immediate increase in blood pressure following subcutaneous 
AngII infusion 
 
We next evaluated the effect of ICV administered wt-CaMKIIα on the slow 
pressor AngII-induced hypertensive model. Similar to the acute AngII studies, 
mice were implanted with radiotelemeters and ICV cannulas for adenovirus 
injections. Following 1 week of recovery from surgery ICV AdGFP and wt-
AdCaMKIIα adenovirus was injected. Blood pressure and heart rate responses 
were recorded in conscious mice after subcutaneous AngII (400 ng/kg/min) or 
saline osmotic minipump implantation 3 days post adenovirus injection. 
Interestingly, blood pressure was significantly elevated following 2 days of AngII 
infusion in wt-AdCaMKIIα-injected mice group and continued to increase 
gradually until day 23 when the minipumps emptied and blood pressure came 
back to basal levels (Figure 3.10A). In contrast, blood pressure in AdGFP-
injected mice increased gradually with AngII infusion with a peak at around day 
16 and then came back to baseline levels at day 23-24 when the osmotic 
minipumps were empty. It should be noted that the blood pressure response 
following subcutaneous AngII infusion in case of AdGFP-injected mice is 
characteristic of a slow pressor AngII-induced hypertensive model. Systolic and 
diastolic blood pressures followed similar pattern as the mean arterial pressure 
(Figure 3.10B and C). Heart rate was not significantly different in between AdGFP 




responses did not differ in case of saline infused animals. Overall, these studies 
indicate that CaMKIIα overexpression in the brain sensitizes mice to an 

























Figure 3.10. Overexpression of wt-CaMKIIα in the brain sensitizes mice to 
an immediate increase in blood pressure following chronic subcutaneous 
AngII infusion. Representative line graphs showing (A) mean arterial pressure, 
(B) systolic blood pressure, (C) diastolic blood pressure and (D) heart rate 
recorded via radiotelemetry in C57BL/6 mice at baseline, following 
intracerebroventricular injection of AdGFP or wt-AdCaMKIIα, and after 
subcutaneous implantation of osmotic minipumps set to release saline or AngII 
(400 ng/kg/min). *P < 0.05 vs. AdGFP mice with AngII infusion. n = 6-9 mice for 








Considering the importance of AngII signaling in central neuronsand its 
contribution to neuro-cardiovascular diseases, such as hypertension and heart 
failure, it is necessary to investigate the intra-neuronal signaling mechanisms 
mediated by AngII and the role of secondary intermediates in AngII-neurogenic 
hypertension.  In central neurons AngII increases intracellular Ca2+, activates 
redox mechanisms including NADPH oxidases, signaling intermediates, and 
transcription factors leading to a variety of physiological and pathophysiological 
responses (13, 84, 86, 115, 213). However, the underlying mechanism by which 
specific redox-sensitive downstream signaling molecules, more specifically 
neuronal calcium/calmodulin-dependent protein kinase IIα (CaMKIIα) modulates 
AngII-signaling in neurons is unclear. We report here that adenoviral-mediated 
overexpression of wt-CaMKIIα in central neurons potentiates the AngII-regulated 
intra-neuronal signaling and the AngII-induced hypertensive response. The main 
findings from these set of studies can be summarized as follows: (1) wt-CaMKIIα 
overexpression in mouse catecholaminergic neurons (CATH.a neurons) 
exacerbates the AngII-mediated inhibition of neuronal K+ channel current (Ikv); (2) 
intracerebroventricular (ICV) injection of wt-CaMKIIα in the brain potentiates the 
central acute AngII-induced pressor response; and (3) ICV injection of wt-
CaMKIIα sensitizes mice to an immediate increase in blood pressure at an initial 
subpressor dose of subcutaneous chronic AngII infusion.  
          Previous studies have identified protein kinases, such as CaMKII and 




(80, 81, 219). For example, two previous studies have shown a clear contribution 
of CaMKII and PKC in mediating the AngII-induced inhibition of neuronal ion 
channels and subsequent increase in neuronal firing both in primary neuronal 
cultures as well as in neuronal cell lines  (80, 136). One previous study from our 
lab has also demonstrated activation of CaMKII by inducing CaMKII 
phosphorylation in AngII-stimulated CATH.a neurons and this CaMKII 
phosphorylation can be blocked by overexpressing mitochondrial-targeted 
manganese superoxide dismutase (83). These studies therefore suggest CaMKII 
as a key player in AngII-mediated signaling in neurons. Additionally, Erickson et 
al. have shown that AngII can induce CaMKIIδ oxidation in cardiomyocytes in a 
paired methionine residue and sustain CaMKIIδ activity independent of 
Ca2+/CaM binding (181). This sustained activity of CaMKIIδ leads to AngII-
mediated apoptosis in ischemic heart and under myocardial infarction conditions. 
Although these studies indicated CaMKII as an important downstream molecule, 
in the present study we wanted to specifically investigate the role of major 
neuronal isoform of CaMKII (CaMKIIα) in mediating AngII intra-neuronal signaling 
and the AngII-induced hypertension.  
            To determine the role of CaMKIIα in mediating the AngII-induced 
reduction in neuronal Ikv, we used adenoviral-mediated overexpression of wt-
CaMKIIα in CATH.a neurons and measured changes in outward K+ current. 
Consistent with previous findings, AngII stimulation inhibited Ikv by almost 16% 
both in non-transduced as well as in AdEmpty-transduced neurons. Interestingly, 




addition to enhancing the AngII effects wt-CaMKIIα overexpression by itself had a 
lower baseline Ikv in CATH.a neurons. To correlate changes in baseline 
electrophysiological properties with ion channel expression we also investigated 
the basal expression levels of different voltage-gated K+ channels that could 
potentially play a role in CaMKIIα-mediated Ikv reduction. Previously Gao et al. 
have shown that in neurons isolated from the rostral ventrolateral medulla of 
chronic heart failure animals as well as in AngII-stimulated CATH.a neurons 
expression of Kv4.3, one of the important voltage-gated K
+ channels, is 
downregulated (85). In the present study we found an upregulation in the basal 
gene expression of four of the voltage-gated K+ channels, Kv2.1, Kv2.2, Kv4.2 and 
Kv4.3 in CATH.a neurons with wt-CaMKIIα overexpression. We speculate that this 
increase in mRNA expression of these channels could be a potential 
compensatory mechanism as a result of wt-CaMKIIα overexpression and 
subsequent inhibition of Ikv. However, further studies are needed to determine the 
protein expression and the cellular localization of these voltage-gated channels in 
wt-CaMKIIα-overexpressed and control neurons.  
             In the central nervous system AngII acts on its type 1 receptor (AT1R) to 
promote vasopressin secretion, thirst and salt appetite, sympathetic outflow and 
also modulates baroreflex sensitivity (73, 199, 212). Brain AngII is known as a 
potent regulator of arterial blood pressure and when administered acutely in an 
ICV route it elicits a classic transient systemic and bradycardic response. As 
seen in Figure 3.8, acute ICV injection of AngII caused a characteristic rapid and 




In contrast the AngII-induced increase in blood pressure was significantly 
potentiated in mice injected with ICV wt-AdCaMKIIα. We did not observe 
changes in baseline blood pressure or heart rate with ICV wt-AdCaMKIIα 
overexpression as opposed to our in vitro patch-clamp data. This could be due to 
a variety of reasons: firstly, our in vitro studies are carried out in a homogenous 
CATH.a neuronal cell population where as in the brain different cell types 
including astrocytes, glial cells and endothelial cells have their own signaling 
pathways but can also interact with neuronal signaling. Secondly, although we 
clearly demonstrate CaMKIIα overexpression in the subfornical organ when given 
ICV, we cannot rule out the possibility that the adenovirus is being taken up by 
other cardiovascular brain nuclei or even some non-cardiovascular brain regions. 
Furthermore, other downstream mechanisms may be involved in vivo to 
counteract any mild change in baseline blood pressure or heart rate that may be 
occurring with wt-CaMKIIα overexpression. 
              The slow pressor chronic AngII-induced hypertensive model has been 
extensively used by our lab and others to investigate intraneuronal signaling 
mechanisms in AngII-mediated neurogenic hypertension (115, 222, 223).  We 
therefore wanted to evaluate the role of ICV wt-CaMKIIα injection on chronic 
subcutaneous AngII infusion and the AngII-induced hypertensive response. 
Consistent with the acute AngII data, ICV wt-CaMKIIα did not alter baseline blood 
pressure (baseline blood pressure ~ 95 mmHg). Intriguingly, we observed a 
significant rise in blood pressure in wt-AdCaMKIIα-injected mice immediately 




injected mice and this was maintained up to 2-3 days post minipump 
implantation. We speculate that mice receiving wt-CaMKIIα injection in the brain 
are being sensitized to an immediate increase in blood pressure at an early 
subpressor dose of chronic subcutaneous AngII infusion. Further studies are 
needed to determine the mechanism of action by which wt-CaMKIIα in the brain 
is sensitizing mice to this immediate rise in blood pressure with subcutaneous 
AngII. Previous studies have shown that CaMKII can activate upstream 
molecules, such as NADPH oxidase and in turn lead to increased generation of 
reactive oxygen species which can then cause CaMKII oxidation thereby 
sustaining CaMKII activity in vascular smooth muscle cells (225). In addition, it is 
also possible that wt-CaMKIIα overexpression in the brain disrupts the blood 
brain barrier integrity as a result of which AngII, immediately following the start of 
infusion, can rapidly access cardiovascular control brain regions which are 
otherwise protected by the blood brain barrier. 
                 In summary, the experimental data presented herein provide new 
evidence supporting neuronal CaMKIIα as an important downstream intermediate 
in AngII-intraneuronal signaling and subsequent AngII-dependent hypertension. 
More specifically, we showed that overexpression of wt-CaMKIIα exacerbates the 
AngII-mediated inhibition of outward K+ current. Additionally, wt-CaMKIIα 
overexpression in the brain subfornical organ potentiates both the acute central 
and the chronic subcutaneous AngII-induced hypertension in mice. These set of 
data led us to examine the effect of mutating redox-sensitive residues in CaMKIIα 









Chapter IV: Mutation of CaMKIIα at Cys280-Met281 attenuates the 
potentiated Angiotensin II intra-neuronal signaling mechanisms mediated 





Our wild-type CaMKIIα (wt-CaMKIIα) studies (Chapter III) indicated that 
overexpression of wt-CaMKIIα exacerbated the AngII-mediated inhibition of K+ 
current in CATH.a neurons. Overexpressing wt-CaMKIIα in the brain subfornical 
organ (SFO), an important cardiovascular regulatory brain nuclei, also 
potentiated the acute AngII-mediated increase in blood pressure response 
(Figure 3.8 Chapter III). Interestingly, in an AngII-infusion hypertensive model, wt-
CaMKIIα overexpression sensitized mice to an immediate increase in blood 
pressure at an initial subpressor dose of subcutaneous AngII. Previous studies 
have shown the importance of the SFO in AngII-mediated hypertension and 
overexpression of copper zinc superoxide dismutase (CuZnSOD) in the SFO 
attenuates the AngII-mediated increase in blood pressure in mice (90). These 
studies therefore indicate the importance of CaMKIIα in mediating AngII-signaling 
in neurons and the AngII-hypertensive response. However, the exact mechanism 
by which AngII-mediated increase in ROS regulate CaMKIIα in neurons is still 
unknown. 
              Past studies have extensively investigated AngII intra-neuronal signaling 
mechanisms both in primary neurons from rat hypothalamus and brain, and also 




current thus increasing neuronal firing frequency (80, 81, 226). However, when 
they used inhibitors to inhibit signaling proteins, such as CaMKII and protein 
kinase C (PKC) the AngII-mediated effects could be significantly blunted thereby 
suggesting a role of CaMKII and PKC in AngII-signaling in central neurons (80, 
81, 219). In addition to neurons, CaMKII in the cradiomyocytes (CaMKIIδ) has 
also been illustrated in AngII-mediated ischemic stress response and apoptosis 
in the heart. Importantly, Erickson et al. showed that in presence of AngII 
stimulation and increased ROS CaMKIIδ undergoes oxidation in a paired 
methionine residue (M281/282) (181, 220). Although Ca2+/CaM is required for the 
initial activation of CaMKII yet oxidation in methionine 281/282 sustains CaMKIIδ 
activity when the Ca2+ stimulus has subsided and the Ca2+/CaM has dissociated. 
Whereas CaMKIIδ along with CaMKIIβ and CaMKIIγ have the paired methionine 
residues at positions 281 and 282, the predominant brain isoform of CaMKII 
(CaMKIIα) instead has a cysteine and methionine at 280 and 281 respectively. In 
order to demonstrate that CaMKIIα is also susceptible to oxidation Erickson and 
colleagues purified CaMKIIα and exposed to pro-oxidant conditions.  They further 
mutated the first methionine of CaMKIIδ with a cysteine to mimic CaMKIIα. 
Interestingly, in presence of H2O2 purified CaMKIIα had increased oxidation 
thereby suggesting the redox-sensitivity of CaMKIIα. Redox-regulation of 
CaMKIIα has also been demonstrated by a nitric oxide (NO)-induced S-
nitrosylation of CaMKIIα in excitotoxic neuronal cell death mechanisms (189). In 
this study, Coultrap et al. showed that NO generates autonomous CaMKIIα 




Inhibition of S-nitosylation in either of those residues abolished CaMKIIα 
autonomy and prevented the NO-induced excitotoxic neuronal cell death. 
Additionally, in hippocampal neurons large increases in cytosolic Ca2+ has been 
associated with mitochondrial O2
- generation which in turn activates protein 
kinases, such as CaMKII (190). Activation of CaMKII by mitochondrial O2
- is 
mediated at least in part by inhibition of inactivating protein phosphatases, such 
as protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1). Taken 
together, these studies suggest the importance of redox regulation of different 
CaMKII isoforms in a variety of pathological conditions (227).  
             In the present study we tested the hypothesis that mutation of redox-
sensitive cysteine and methionine residues in CaMKIIα (C280A/M281V) 
attenuates the AngII-mediated inhibition of neuronal K+ channel current and the 
AngII-induced hypertensive response in mice. We show that mut-CaMKIIα 
attenuates the potentiated AngII response following wt-CaMKIIα overexpression 
in CATH.a neurons. In addition, mut-CaMKIIα in the brain prevents the 





CATH.a neuronal cell culture 
 
For detailed descriptions of mouse CATH.a neuronal cell culture and 




Site-directed mutagenesis and mutant CaMKIIα adenovirus generation 
 
 
Replication-deficient recombinant adenovirus (Ad5-CMV) encoding mouse 
mutant calcium/calmodulin-dependent protein kinase IIα (mut-AdCaMKIIα) was 
generated. Primer sequences were made specifically to mutate cysteine 280 to 
alanine and methionine 281 to valine with overlapped extension polymerase 
chain reaction (PCR). Briefly two sections of the wt-CaMKIIα plasmid (Origene) 
were amplified by conventional PCR using HotStart PCR Master Mix (Qiagen, 
Venlo, Limburg) with the following two set of primers: Section 1 forward 5’- GAA 
TTC ATG GCT ACC ATC ACC TGC ACC C – 3’; reverse 5’ – CCA CGG TCT 
CCT GTC TGT GCA - 3’. Section 2 forward 5’- GTG CAC AGA CAG GAG ACC 
ACC GTG – 3’; reverse 5’ – GGA TCC TCA ATG CGG CAG GAC GGA - 3’. For 
description on cloning using pJet1.2 PCR clone jet kit (Thermo Scientific) and 
bacterial colony culture see experimental methods in Chapter III. Adenoviral 
vectors encoding mut-CaMKIIα were constructed, purified and provided by the 
University of Iowa Gene Vector Core as previously described (83, 221).  
RNA extraction, cDNA and quantitative real-time RT-PCR 
 
 
CaMKII mRNA levels were measured in CATH.a neurons following adenovirus-
mediated transduction of mut-CaMKIIα. Real-time RT-PCR was utilized as 
previously described in experimental methods of Chapter III. mRNA levels of 
voltage-dependent K+ channels, such as Kv2.1, Kv2.2, Kv4.2 and Kv4.3 were also 
detected in CATH.a neurons following adenoviral transduction. To confirm the 




injections, micro punches of the SFO along with ventricular tissues were 
collected and then RNA was extracted in Trizol reagent. 
Western blot analysis 
 
 
Total and phosphorylated CaMKIIα protein expression was detected in CATH.a 
neurons following adenoviral transduction at different multiplicity of infection. For 
description of Western blotting protocol, see experimental methods in Chapter III.  
Electrophysiological record of voltage-gated K+ currents 
 
 
For description of whole-cell patch-clamp technique to record voltage-gated K+ 
current, see experimental methods in Chapter III. Voltage-gated K+ currents were 
recorded in non-transduced, AdEmpty (25MOI), wt-AdCaMKIIα (25MOI) and mut-
AdCaMKIIα (25MOI) at baseline and following 5 minutes of AngII (100 nM) 
superfusion. To confirm the AngII-mediated response on K+ channel currents, 
AngII was washed out and K+ current was recorded for 15 minutes. 
In vivo mouse studies – radiotelemetry implantation, 
intracerebroventricular cannula placement and osmotic minipump 
implantation 
 
All animal procedures were performed as described in experimental methods of 
Chapter III, in accordance with Guidelines for the Care and Use of Experimental 
Animals of the American Physiological Society and the National Institutes of 
Health, with specific experimental protocols being reviewed and approved by the 




Committee. Mice received left carotid artery radiotelemeters to measure 
cardiovascular parameters such as mean arterial pressure, systolic pressure, 
diastolic pressure, heart rate and pulse pressure. Cannulas were implanted 
intracerebroventricularly to inject control adenovirus (AdGFP) and mut-CaMKIIα 
adenovirus. Both the adenoviruses were injected at 5 x 107 plaque forming units. 
It is to be noted that mice for these set of in vivo studies did not receive central 
acute AngII injections. ICV adenovirus injections were followed by saline and 
AngII subcutaneous osmotic minipump implantation to establish the AngII-infused 
mouse model of hypertension. The slow pressor dose infusion rate of 400 




Mouse brains were collected 7 days post-ICV AdGFP or mut-AdCaMKIIα 
injections and 20 µm sections of the brains were prepared using a cryostat (Leica 
CM3050S). The sections were incubated at 4 ºC overnight with a rabbit primary 
antibody against CaMKIIα (1:200, abcam) and a rabbit P-CaMKIIα (1:200, 
abcam) prepared in 0.1 M PB containing 2% NHS and 0.3% Triton X-100. Alexa 
Fluor 598 secondary antibody (1:200, Invitrogen) was then used to incubate the 
brain sections at room temperature for 2 hours. Fluorescent images of the 
subfornical organ and ventricles were detected by confocal laser scanning 
microscopy (Zeiss LSM 510 Meta Confocal Microscope) at 20X and 40X 
magnification. For detailed immunohistochemical staining procedure, see 








All data are presented as means ± standard error of the mean (SEM). Data were 
analyzed by Student’s t-test for two group comparisons or by ANOVA with 
Newman Kewls post-hoc test. P-value less than 0.05 was considered statistically 
significant. Statistical analyses were performed using GraphPad Prism 5.0 




Adenoviral-mediated transduction of mut-CaMKIIα increases total and 
phosphorylated CaMKIIα protein in CATH.a neurons 
 
To check if the mut-CaMKIIα adenovirus expresses CaMKIIα protein, we first 
detected total CaMKIIα protein expression in non-transduced CATH.a neurons 
and neurons transduced with AdEmpty and mut-AdCaMKIIα at 10, 25 and 
50MOI. CaMKIIα protein was significantly overexpressed in all the mut-
AdCaMKIIα transduced groups (Figure 4.1A,B); however, in order to be 
consistent with our wt-CaMKIIα in vitro studies we selected the 25MOI of the 
adenovirus for the next set of cell culture experiments. Phosphorylated CaMKIIα 
levels were also increased in CATH.a neurons transduced with mut-CaMKIIα 
adenovirus as compared to the non-transduced and AdEmpty-transduced 
neurons (Figure 4.1A,C). To determine mRNA levels of CaMKIIα we utilized real-




Primers specific for CaMKIIα revealed a significant increase in CaMKIIα mRNA in 
CATH.a neurons transduced with mut-CaMKIIα adenovirus (Figure 4.1D). The 
other CaMKII isoforms, such as CaMKIIβ and CaMKIIδ did not change 
significantly in between the non-transduced, AdEmpty, and mut-AdCaMKIIα 
groups (Figure 4.1 E, F). Kinase activity assay was utilized to measure CaMKII 
activity in AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI) and mut-AdCaMKIIα-
transduced CATH.a neurons. Neurons with wt-CaMKIIα overexpression had 3-
fold higher activity as compared to AdEmpty-transduced neurons. CaMKII activity 
in mut-AdCaMKIIα group was lower than wt-CaMKIIα transduced neurons but 






































Figure 4.1. Transduction of mut-AdCaMKIIα causes significant upregulation 
of CaMKIIα expression in CATH.a neurons. (A) Representative Western blot 
analysis of CATH.a neuronal cell lysates probed for primary antibody against total 
and phosphorylated CaMKIIα; Summary densitometry data of Western blot 
analysis showing levels of (B) CaMKIIα and (C) P-CaMKIIα in non-transduced, 
AdEmpty (10, 25 and 50 MOI)- and mut-AdCaMKIIα (10, 25 and 50 MOI)-
transduced neurons; Real-time RT-PCR data with primers specific for CaMKIIα 
(D), CaMKIIβ (E), and CaMKIIδ (F) genes normalized to 18s rRNA and 
expressed as fold control. (G) CaMKII activity in AdEmpty (25MOI) and wt-
AdCaMKIIα (25MOI) and mut-AdCaMKIIα-transduced neruons as measured by 
kinase activity assay and reported as fold change from control. *P<0.05 vs. non-





AngII-mediated increased inhibition of K+ current following wt-CaMKIIα 
overexpression is rescued in mut-CaMKIIα-transduced CATH.a neurons 
 
Whole-cell configuration of the patch-clamp technique was utilized to record 
voltage-gated K+ current (Ikv) in non-infected and adenovirus transduced CATH.a 
neurons at baseline and following 5 minutes of AngII (100 nM) superfusion. 
Neurons transduced with mut-CaMKIIα adenovirus showed similar percent 
inhibition (13%) in Ikv when compared to non-transduced (16%) and AdEmpty 
(16%)-transduced CATH.a neurons (Figure 4.2). Interestingly, when compared to 
wt-CaMKIIα data as presented in Chapter III (37% inhibition of outward K+ 
current) the restoration in the AngII-mediated reduction in Ikv with mut-CaMKIIα 
was significant. Both transient and steady-state K+ current followed a similar 
pattern. To note, the Ikv data in the non-transduced, AdEmpty and wt-AdCaMKIIα 









Figure 4.2. Mut-CaMKIIα transduction restores the potentiated AngII-
mediated inhibition of outward K+ current in CATH.a neurons. Percent 
inhibition of outward K+ current following 5 minutes of AngII (100 nM) superfusion 
in non-transduced, AdEmpty (25MOI) or mut-AdCaMKIIα (25 MOI)-transduced 
CATH.a neurons (n = 4-7 biological replicates for all experimental groups). *P < 






Mutant CaMKIIα transduction does not change mRNA levels of voltage-
dependent K+ channels in CATH.a neurons 
 
To determine the outcome of mut-CaMKIIα expression on voltage-dependent K+ 
channels, real-time RT-PCR was utilized to measure mRNA levels of Kv2.1, Kv2.2, 
Kv4.2 and Kv4.3 in CATH.a neurons. Baseline expression of the channels was 
detected in AdEmpty (25MOI) and mut-AdCaMKIIα transduced neurons. Initial 
experiments showed a modest decrease in Kv2.1, and Kv4.2 and Kv4.3 mRNA 
expression in mut-CaMKIIα transduced neurons as compared to AdEmpty; 
however, the data did not reach statistical significance. Surprisingly Kv2.2 mRNA 





                  
 
 
           
 
Figure 4.3. Mut-CaMKIIα modestly decrease mRNA expression of voltage-
dependent K+ channels in CATH. neurons. Quantitative real-time PCR 
analysis showing (A) Kv2.1, (B) Kv2.2, (C) Kv4.2 and (D) Kv4.3 mRNA levels in 
AdEmpty (25MOI) and mut-AdCaMKIIα (25MOI) transduced CATH.a neurons. 







Intracerebroventricular injections of mut-CaMKIIα adenovirus increases 
CaMKIIα expression in brain subfornical organ of mice 
 
Mice were implanted with ICV cannulas to receive central injections of AdGFP 
and mut-AdCaMKIIα adenovirus. The expression of CaMKIIα in the brain SFO 
was confirmed by immunohistochemistry 7 days post ICV adenovirus injections. 
CaMKIIα was greatly increased in mice receiving mut-CaMKIIα adenovirus as 
compared to AdGFP group (Figure 4.4A). Interestingly, levels of P-CaMKIIα did 
not increase as seen in our previous studies with wt-CaMKIIα overexpression in 
the SFO (Figure 4.4A). CaMKII mRNA levels were also detected by real-time RT-
PCR in brain SFO micropunches following ICV adenovirus injections. The mRNA 
level for CaMKIIα was significantly increased by ~12 fold in mice receiving mut-
CaMKIIα injections (Figure 4.4B). Interestingly, another CaMKII isoform 
(CaMKIIβ), which has a wide tissue distribution and is also present in the brain, 
was increased by 3 fold. The mRNA levels of other CaMKII isoforms (CaMKIIδ 
































Figure 4.4.  Adenoviral-mediated overexpression of CaMKIIα in the 
subfornical organ (SFO). (A) Representative confocal microscopy images 
showing expression of GFP, CaMKIIα and P-CaMKIIα in SFO of mice 1 week 
after intracerebroventricular (ICV) injection of AdGFP or mut-AdCaMKIIα. 
Coronal brain sections (20 µm) were stained for GFP (green), total and 
phosphorylated CaMKIIα (red). (B) Real-time PCR data showing relative mRNA 
expression of CaMKIIα, CaMKIIβ, CaMKIIδ and CaMKIIγ genes in brain 
micropunches. Values are normalized to 18S rRNA and expressed as relative to 






Mutant CaMKIIα expression in the brain subfornical organ prevents the 
sensitization mechanism following AngII infusion  
 
Mice received ICV injections of AdGFP or mut-CaMKIIα adenovirus prior to 
minipump implantation. Baseline blood pressure was recorded with 
radiotelemetry for 3 days following which subcutaneous saline and AngII osmotic 
minipumps were implanted. Interestingly, mice which received ICV mut-
AdCaMKIIα had a modest increase in blood pressure on days 1-2 after AngII 
infusion but declined to near baseline levels on day 3. Blood pressure then 
gradually increased in mice receiving mut-AdCaMKIIα with AngII infusion (Figure 
4.5A). This increase in mean arterial pressure (MAP) was similar to the AdGFP 
mice with AngII infusion and is characteristic of the slow-pressor AngII-
hypertensive model (222, 223). The peak AngII response on days 15-17 was lower 
in mut-AdCaMKIIα group (115 mmHg) as compared to the AdGFP group (125 
mmHg). Importantly, when compared to the wt-CaMKIIα data (peak AngII 
response – 133 mmHg), as presented in results of Chapter III, the peak AngII 
response is significantly attenuated in the mut-AdCaMKIIα group and the 
sensitization mechanism that is seen immediately following AngII infusion in the 
wt-CaMKIIα overexpression mice is prevented with mut-CaMKIIα expression. 
Blood pressures came back to baseline levels on day 22-23 for each group when 
the minipumps were empty. Systolic and diastolic blood pressures followed a 
similar pattern as the MAP (Figure 4.5C, D). Heart rate did not differ between the 























Figure 4.5. Intracerebroventricular injection of mut-CaMKIIα in the brain 
and chronic infusion of subcutaneous AngII via osmotic minipumps. 
Representative line graphs showing (A) mean arterial pressure, (B) heart rate, 
(C) systolic blood pressure, and (D) diastolic blood pressure and via 
radiotelemetry in C57BL/6 mice at baseline, following intracerebroventricular 
injection of AdGFP or mut-AdCaMKIIα, and after subcutaneous implantation of 
osmotic minipumps set to release saline or AngII (400 ng/kg/min). *P < 0.05 vs. 
wt-AdCaMKIIα mice with AngII infusion and #P < 0.05 vs. AdGFP mice with AngII 







Calcium/calmodulin-dependent protein kinase II (CaMKII) belongs to a 
multifunctional family of serine/threonine protein kinases. Different isoforms of 
CaMKII have diverse roles and distribution and their function is often determined 
by the tissues in which they are expressed. For examples, numerous studies 
have shown that CaMKII in neuronal tissues play important role in memory and 
synaptic plasticity (228). On the other hand, in T lymphocytes, CaMKII have a 
major role in regulation of CD8 T cell proliferation, cytotoxic effector function and 
response to re-stimulation (228). In central neurons, the AngII-mediated 
regulation of ion channels has elucidated the involvement of CaMKII as a 
downstream signaling molecule in AngII-intraneuronal signaling pathways (80, 
219). Additionally, increased reactive oxygen species (ROS) can also act as 
signaling intermediates in AngII signaling pathway in neurons. However, the 
exact mechanism by which AngII and increased ROS regulates CaMKII in 
neurons, specifically the major neuronal isoform of CaMKII (CaMKIIα) is unclear. 
In the present study we report that: (1) mutation of redox-sensitive cysteine and 
methionine residues in CaMKIIα restores the potentiated AngII-mediated K+ 
current inhibition, (2) intracerebroventricular injection of mutant CaMKIIα 
adenovirus in brain subfornical organ of mice prevents the initial sensitization 
following AngII infusion, and (3) mutant CaMKIIα expression in the brain 
significantly attenuates the AngII-induced peak rise in blood pressure as 
compared to wt-CaMKIIα overexpressed mice. 




CaMKIIδ undergoes oxidation in paired methionine residues (met 281/282) 
present in the regulatory domain (181). Oxidation in methionine residues sustain 
CaMKIIδ oxidation in absence of Ca2+/CaM. They further showed that AngII-
induced CaMKIIδ oxidation leads to cardiomyocyte apoptosis. However, neuronal 
CaMKIIα differs from the other CaMKII isoforms because of the presence of a 
cysteine and methionine in positions 280 and 281 respectively. Importantly, in 
presence of increased mitochondrial superoxide, CaMKII in hippocampal 
neurons have increased kinase activity (190). This increase in CaMKII activity is 
mediated at least in part by inhibition of protein phosphatases that regulate 
CaMKII autophosphorylation state. Moreover, recent studies by Coultrap and 
Bayer demonstrated that in addition to oxidation, cysteine residues in CaMKIIα 
are also susceptible to nitric oxide-mediated S-nitrosylation (189). In their study 
they investigated the susceptibility of two cysteines at positions 280 and 289 to 
S-nitrosylation and showed that mutation of either cysteine prevents NO-induced 
excitotoxic neuronal cell death. Although these studies indicate the redox-
sensitivity of CaMKIIα, we wanted to specifically determine the outcome of 
mutating C280/M281of CaMKIIα on AngII-intraneuronal signaling mechanisms. 
Furthermore, we wanted to compare the effect of CaMKIIα mutation with our wt-
CaMKIIα overexpression studies by looking at AngII-mediated K+ current 
inhibition and the AngII-induced hypertension. 
              First, we wanted to investigate the effect of mut-CaMKIIα on AngII-
mediated inhibition of K+ current. Voltage-dependent K+ current (Ikv) was 




AdEmpty and mut-CaMKIIα adenovirus at 25MOI. Interestingly, the percent 
inhibition of Ikv in all the three groups was approximately similar with a modest 
decrease observed in mut-CaMKIIα transduced neurons. However, when 
compared with the wt-CaMKIIα data from Chapter III, it is evident that the 
exacerbated AngII-mediated inhibition of Ikv with wt-CaMKIIα overexpression is 
restored with mutation of CaMKIIα. Importantly, as previously mentioned in 
Chapter III discussion, CATH.a neurons do not appear to have endogenous 
CaMKIIα and this may explain why CaMKIIα mutation does not completely 
abolish the AngII-mediated Ikv inhibition. Other protein kinases, such as PKC or 
CaMKIIβ may play a role in mediating AngII-downstream signaling in CATH.a 
neurons. These studies therefore confirm that redox-regulation of CaMKIIα plays 
an important role in AngII-signaling in central neurons. 
             Since wt-CaMKIIα overexpression elucidated a potential compensatory 
mechanism in the transcriptional upregulation of different voltage-dependent K+ 
channels, we wanted to determine whether mut-CaMKIIα has any role in the 
regulation of these channels. To do that, we utilized real-time RT-PCR and 
measured mRNA levels of Kv2.1, Kv2.2, Kv4.2 and Kv4.3 in CATH.a neurons 
transduced with either AdEmpty or mut-AdCaMKIIα. From these initial studies we 
observed that there was no significant different in mRNA expression of any of the 
channels between the two groups. This data once again confirms the 
compensatory mechanism that overexpression of wt-CaMKIIα lowers baseline Ikv 
which then leads to the transcriptional upregulation of these channels.  




chronic subcutaneous AngII infusion and the AngII-induced hypertensive 
response in mice. Consistent to wt-CaMKIIα overexpression ICV mut-CaMKIIα 
did not alter baseline blood pressure and heart rate. Intriguingly we observed a 
similar rise in blood pressure in mut-AdCaMKIIα injected mice for 2 days 
immediately after the start of AngII infusion as observed with wt-CaMKIIα mice. 
However, blood pressure came back to baseline levels after 2 days of AngII 
infusion and continued to rise gradually as AdGFP mice infused with AngII. This 
is the characteristic slow pressor chronic AngII-induced hypertensive model that 
has been extensively used by our lab and others to study AngII-mediated 
neurogenic hypertension. We speculate that the immediate increase in blood 
pressure in mice with mut-CaMKIIα occurs as a result of some forms of active 
CaMKIIα already present in the brain other than oxidized form. This can happen 
as a result of autophosphorylation of CaMKIIα in threonine 286 residue and can 
prolong CaMKIIα activity in absence of Ca2+/CaM. However, with increase in 
AngII levels in the brain and the increase in reactive oxygen species, mut-
CaMKIIα is prevented from being oxidized as opposed to wt-CaMKIIα. This in 
turn prevents the sustained CaMKIIα activation and the rise in blood pressure 
follows the characteristic pattern of slow-pressor AngII-induced hypertension. 
Since recent studies have indicated potential S-nitrosylation of CaMKIIα in 
cysteine 280/289 (199), it would be interesting to see if mutation of cysteine 289 
in addition to the C280/M281 can further attenuate the AngII-induced peak 
increase in blood pressure and whether it would have an effect on the initial rise 




              In summary, the experimental data presented herein provide important 
insight on the role of redox-sensitive CaMKIIα in AngII-intraneuronal signaling 
and subsequent AngII-dependent hypertension.  More specifically, we showed 
that mutation of CaMKIIα at cysteine 280 and methionine 281 restores the 
exacerbated AngII-mediated inhibition of outward K+ current observed with wt-
CaMKIIα overexpression. Additionally, mut-CaMKIIα in the brain subfornical 
organ prevents the early sensitization mechanism and lowers the peak AngII-
response in a slow-pressor AngII-hypertensive model. In conclusion these 
studies may help to identify potential therapeutic targets, such as CaMKIIα, in the 






Chapter V: Conclusion 
Overall summary of findings and discussion 
 
Dysregulation of angiotensin II (AngII) signaling in the central nervous system 
(CNS) is involved in the pathogenesis of cardiovascular disorders, including 
hypertension and heart failure (73, 89, 214, 229). Several components of the 
renin-angiotensin system (RAS) including AngII have been shown to be elevated 
both in periphery as well as in the brain during these diseases (87, 88, 191). 
Numerous studies so far have investigated the AngII-intraneuronal signaling 
mechanisms associated with the pathogenesis of hypertension and heart failure. 
One such mediator of AngII signaling in neurons is reactive oxygen species 
(ROS) (56, 90, 112, 139, 230). Imbalance between the ROS producing 
components and the antioxidant defense mechanisms can lead to downstream 
pathological responses of AngII (96, 110).By acting on the type 1 receptor (AT1R) 
AngII leads to physiological responses such as vasoconstriction, sympathetic 
nervous system activation, sodium and water reabsorption, vascular and cardiac 
remodeling, inflammation, fibrosis, thrombosis, and release of aldosterone (ALD), 
and vasopressin (AVP) (10, 22). Clinically, the common therapeutics used for the 
treatment of diseases, like hypertension, consist of RAS blockers, such as 
angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers 
(ARBs) in addition to β-adrenergic receptor blockers (β-blockers) (231). However, 
according to a report released by the Center for Disease Control and Prevention 
(CDC) in 2012, inspite of taking the above mentioned medications, approximately 




blood pressures controlled (7). Since enhanced activation of RAS and elevated 
AngII levels in the brain are implicated in hypertension therefore it is of utmost 
importance to understand the intracellular signaling mechanisms mediated by 
AngII in neurons in order to identify novel therapeutic targets to treat neuro-
cardiovascular diseases. 
            In AngII-stimulated central neurons, the two major sources of ROS 
production are the nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases (NOX) and the mitochondria (99, 103, 139). Both the sources primarily 
lead to an increase in superoxide (O2
-) and hydrogen peroxide (H2O2). In 
addition to electron leakage from the mitochondrial electron transport chain 
(ETC) leading to excessive ROS production (102, 103), recent studies from our 
lab have shown that NOX localized in neuronal mitochondria can also increase 
mitochondrial ROS levels (115). In addition, proinflammatory cytokines activated 
by AngII signaling also generate ROS in the brain (109, 232). The increased O2
- 
can then regulate ion channels thereby modulating the channel currents to 
increase neuronal firing rate and neuronal activation. For example, studies by 
Sumners and colleagues have shown that in central neurons, AngII inhibits K+ 
current and this in turn leads to an increase in neuronal firing frequency (79-81). 
Furthermore, our lab has showed that this reduction in K+ current mediated by 
AngII can be attenuated by scavenging O2
- with specific scavenging enzymes, 
such as copper zinc superoxide dismutase (CuZnSOD) and manganese 
superoxide dismutase (MnSOD) (83). Neuronal firing can also be increased by 




shown to increase intracellular Ca2+ levels in a neuronal cell line (84). 
Additionally, Sumners and Raizada have shown that the the AngII-mediated 
reduction in K+ current and the increased neuronal firing frequency can be 
attenuated by inhibiting some of the Ca2+ dependent enzymes, such as protein 
kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII) 
(80, 81). 
              In the brain AngII can activate neurons in the circumventricular organs 
(CVOs), which abundantly express the AT1R (64, 75, 233). The CVOs are devoid 
of an intact blood brain barrier (BBB) and is therefore exposed to circulating 
peptides and hormones. One such CVO is the subfornical organ (SFO), which 
lies in the roof of the third ventricle and is an important cardiovascular regulatory 
brain nucleus (90, 110). The importance of SFO in AngII-mediated signaling was 
shown by lesioning the SFO that abrogated the hypertensive response induced 
by circulating AngII (45, 60).  Furthermore, adenoviral-mediated overxpression of 
CuZnSOD in the SFO scavenges the AngII-induced O2
- and attenuates 
sympathetic drive and blood pressure in numerous animal models of 
hypertension (90).  
             The family of multifunctional calcium/calmodulin (Ca2+/CaM)-dependent 
protein kinases (CaMKs) including CaMKI, CaMKII and CaMKIV modulate many 
of the cellular responses to Ca2+. These downstream effector molecules translate 
and co-ordinate the dynamic second messenger, Ca2+, into appropriate cellular 
responses by a highly specific and reversible phosphorylation of a number of 




kinases has both common as well as unique features with respect to their 
structure, regulation and activation. The CaMKII is responsible for the coupling of 
Ca2+ increase to ion channel activation, gene transcription, neurotransmitter 
synthesis and release, cytoskeletal organization and apoptosis (181-183). 
Classically, CaMKII is activated by the binding of Ca2+/CaM followed by 
autophosphorylation in the regulatory domain. Autophosphorylation confers the 
kinase activity of CaMKII which can then phosphorylate specific serine and 
threonine residues of target proteins. Active CaMKII is switched back to the 
inactive resting form by dephosphorylation by specific phosphatases such as 
protein phosphatase 1 (PP1) or protein phosphatase 2A (PP2A) (184-
186).Interestingly, recent studies have shown that the AngII-mediated 
pathological responses in the heart involve a second mechanism of sustained 
CaMKII activation under oxidant conditions which is independent of Ca2+/CaM. 
More specifically, studies by Erickson et al. have demonstrated that oxidation of a 
paired methionine residue (M281/282) in the cardiomyocyte isoform of CaMKII 
(CaMKIIδ) is a downstream signal for AngII and ischemic stress response in the 
heart and inhibition of CaMKIIδ protects the heart against AngII-mediated 
apoptosis and other pathological myocardial responses (181, 187). Since, the 
paired methionine residue is conserved in all three isoforms of CaMKII except the 
predominant neuronal isoform of CaMKII (188) (CaMKIIα) (CaMKIIα has a 
cysteine residue in position 280 instead of the first methionine of the pair), they 
also generated a M281C mutant of CaMKIIδ and also purified CaMKIIα. Both 




the importance of cysteine in ROS-dependent CaMKII activation. More recently, a 
nitric oxide (NO)-mediated S-nitrosylation of CaMKIIα has been implicated in 
excitotoxic neuronal cell death. The results from that study show that specific S-
nitrosylation of C280/289 generated autonomous activation of CaMKIIα 
independent of Ca2+/CaM binding and mutation of either site protected from NO-
induced neuronal cell death(189). The redox sensitivity of CaMKII has also been 
illustrated in studies where large increases in cytosolic Ca2+ causes mitochondrial 
O2
- generation and upregulation of CaMKII in hippocampal neurons(190). 
Activation of CaMKII by this mitochondrial-induced O2
- is also mediated at least 
in part by oxidative suppression of protein phosphatases that dephosphorylate 
CaMKII. Studies by Yin et al. have also showed that in CATH.a neurons AngII 
increases CaMKII phosphorylation, causing CaMKII activation, with a significant 
increase observed after 5 minutes of AngII stimulation. However, neurons, which 
were transduced with AdMnSOD (adenovirus overexpressing manganese 
superoxide dismutase) had reduced CaMKII phosphorylation, indicating that 
ROS is involved at least in past in mediating AngII-induced CaMKII activation in 
central neurons (83). Although these studies convincingly demonstrate the redox 
sensitivity of CaMKII in physiological and pathological responses, the specific 
role of redox regulation of neuronal CaMKIIα in AngII-intraneuronal signaling and 
the AngII-induced hypertensive response is unknown. 
                 Considering the importance of AngII intra-neuronal signaling in the 
pathogenesis of diseases including hypertension and heart failure, numerous 




signaling mechanisms both in vivo and in vitro. However, due to the technical 
challenges in studying AngII-induced intra-neuronal signaling in vivo in animal 
models of hypertension and heart failure as discussed in Chapter II, neuronal cell 
culture models have been frequently utilized to examine the specific intra-
neuronal signaling pathways induced by AngII (80, 86). Nevertheless, there are 
also limitations in using neuronal cell culture models to recapitulate the AngII 
intra-neuronal signaling events occurring in vivo such as: 1) neuronal cells are 
often immortalized and/or isolated from a tumor; 2) cells are usually cultured in a 
hyperoxic environment (i.e. 21% oxygen) as compared to their in vivo 
environment (1-4% oxygen); and 3) the lack of neighboring glia and endothelial 
cells may alter a particular response in the cultured neurons that would normally 
occur in vivo. A fourth limitation in using neuronal cell culture models as it 
specifically relates to understanding AngII intra-neuronal signaling is the lack of 
evidence indicating the stability of exogenous AngII in neuronal cell culture 
media. Many studies have examined intra-neuronal responses, such as changes 
in mRNA levels and protein expression, 1-48 hours after a single administration 
of exogenous AngII into the neuronal cell culture media (200-202). Data from 
these studies are often interpreted to indicate that the observed changes are also 
occurring in neurons of various hypertensive and heart failure models in which 
circulating and/or brain levels of AngII are chronically elevated (203, 204). 
However, it remains unclear if a single treatment of exogenous AngII given to 
neurons in culture results in a chronic elevation of AngII levels in the media. 




intraneuronal signaling, we began by measuring levels of AngII in our CATH.a 
neuronal cell culture media following a single AngII (100 nM) administration. 
Using liquid chromatography and tandem mass spectrometry, we were able to 
detect AngII levels in culture media. Importantly, AngII declined to near basal 
levels 3 hours post the single exogenous AngII administration. Levels of two of 
the AngII metabolites, AngIII and Ang1-7 modestly, but significantly increased in 
the media after 15-60 minutes of AngII administration. Furthermore, replenishing 
the neuronal media with fresh AngII every 3 hours resulted in chronically elevated 
levels of AngII. It should be noted that as a result of differential expression of 
AngII receptors and other components of the RAS, the stability of exogenous 
AngII in cultured media will be drastically different in various cell types. In 
addition, enzymes involved in AngII metabolism, such as aminopeptidase A 
(APA) and angiotensin converting enzyme 2 (ACE2) may also have different 
expression levels depending on the cell type thereby influencing AngII stability in 
the media.  
                Next, to determine the redox-regulation of CaMKIIα and its role in 
AngII-signaling in neurons, we compared adenoviral-mediated overexpression of 
wild-type CaMKIIα (wt-CaMKIIα) to an oxidation-resistant mutant CaMKIIα (mut-
CaMKIIα) in modulating AngII-regulated neuronal K+ channel current and the 
AngII-induced neurogenic hypertension in mice. In an attempt to determine the 
functional relevance of overexpressing wt-CaMKIIα on AngII-signaling in 
neurons, we cloned the wt-CaMKIIα gene and an adenovirus (wt-AdCaMKIIα) 




studies, we confirmed the adenovirus-mediated overexpression of total and 
active wt-CaMKIIα protein with increasing multiplicity of infection (MOI) in 
CATH.a neurons. Both 25MOI and 50MOI of the adenovirus transduction yielded 
significant overexpression of total and phosphorylated (active) wt-CaMKIIα 
protein as detected by Western blot analysis. It should be noted that in order to 
avoid any cytotoxicity with a higher MOI of adenovirus, all the subsequent in vitro 
cell culture experiments were done in the presence of 25MOI of wt-AdCaMKIIα. 
Wt-CaMKIIα was also transcriptionally upregulated as evident by the mRNA 
levels measured by RT-PCR. We also looked for transcriptional upregulation of 
other CaMKII isoforms following overexpression of wt-CaMKIIα. However, mRNA 
levels of the other CaMKII isoforms did not change confirming the specificity of 
the adenovirus for CaMKIIα. To note, although CaMKIIα is predominantly present 
in neurons; however, CATH.a neurons have very little to non-detectable levels of 
basal CaMKIIα as compared to the other CaMKII isoforms as evident by the very 
high cycle number in the RT-PCR analysis (Chapter III). Thus, CATH.a neurons 
serve as an appropriate cell culture model to study the role of CaMKIIα in 
mediating the downstream signaling effects of AngII in neurons. However, the 
presence of other CaMKII isoforms should also be considered while analyzing 
some of the AngII data in CATH.a neurons.  
               We next set out to examine the effect of wt-CaMKIIα overexpression on 
the AngII-mediated inhibition of K+ current. To perform these set of experiments 
we collaborated with Dr. Yulong Li and his lab in the department of Cellular and 




technique was used to record voltage-gated K+ current in differentiated mouse 
CATH.a neurons at baseline and post 5 minutes of AngII superfusion. K+ current 
was also measured after AngII washout for 15 minutes in order to confirm the 
changes observed with AngII superfusion. The percent inhibition in peak and 
steady-state K+ current following AngII stimulation was approximately 16% in 
both non-transduced and AdEmpty-transduced CATH.a neurons. However, in 
neurons where wt-CaMKIIα was overexpressed, the AngII-mediated percent 
inhibition in K+ current was almost 37%, which is significantly higher than the 
non-transduced and AdEmpty group. Baseline K+ current was also modestly 
lower in the wt-AdCaMKIIα-transduced CATH.a neurons as compared to the 
other two groups. Simultaneous experiments were performed where K+ current 
was recorded in the three groups in the presence of a CaMKII inhibitor, KN-93. 
Neurons were pretreated with KN-93 for 30 minutes and then baseline current 
was measured followed by AngII superfusion and washout. Interestingly, the 
AngII-mediated percent inhibition in K+ current was completely abolished in all 
the three groups when pretreated with KN-93.  
                It is important to consider that the presence of other CaMKII isoforms 
in CATH.a neurons, as demonstrated by the mRNA data, may account for the 
AngII-mediated reduction in K+ current in the non-transduced and AdEmpty-
transduced neurons. Moreover, as illustrated by previous studies that PKC is also 
involved in the AngII-intraneuronal signaling (80, 81), we speculate that CATH.a 
neurons may have basal PKC levels which contribute to the AngII-regulation of 




CaMKII, it can inhibit different CaMKII isoforms in CATH.a neurons thereby 
completely attenuating the AngII response in all the three groups. Taken together, 
these studies identified CaMKIIα as one of the mediators of AngII signaling and 
its involvement in the exacerbated reduction of K+ current in AngII-stimulated 
neurons.  
                 To determine the causal relationship between overexpression of wt-
CaMKIIα and the significant reduction in K+ current in CATH.a neurons, we 
sought to detect the mRNA expression of specific voltage-dependent K+ channels 
which have previously been shown to be present in important autonomic regions 
of the brain and also involved in AngII signaling in neurons (85, 224, 234). 
Surprisingly, wt-CaMKIIα overexpression modestly but not significantly increased 
the basal mRNA expression of Kv2.1, Kv2.2, Kv4.2 and Kv4.3 as compared to non-
transduced or AdEmpty-transduced groups. We speculate that transcriptional 
increase in Kv channels may act as a compensatory mechanism to 
counterbalance the reduction in K+ current following wt-CaMKIIα overexpression 
in CATH.a neurons. It is also important to consider that the protein expression of 
these voltage-dependent K+ channels was not examined. Moreover, the cellular 
localization of these voltage-gated channels is crucial for their function and 
transcriptional up regulation does not necessarily indicate increased membrane 
localization. 
                 We next investigated the outcome of wt-CaMKIIα overexpression in 
mouse brain on the acute central AngII-induced pressor response. To compare 




injected AngII (350 ng) intracerebroventricularly (ICV) to specifically target the 
SFO. Central AngII injections elicited the characteristic rapid transient increase in 
blood pressure. Interestingly, 3 days post ICV adenovirus injections the central 
acute AngII-induced rise in blood pressure was significantly potentiated in wt-
CaMKIIα overexpressed mice as compared to AdGFP injected mice. In addition 
to the increased peak changes in mean arterial pressure (MAP), the duration of 
the AngII-response was also greater in wt-CaMKIIα overexpressed group. To 
confirm CaMKIIα overexpression in the SFO, we stained mouse brain sections 
for total and phosphorylated CaMKIIα protein and found a prominent increase in 
CaMKIIα expression in the SFO. These data indicate that overexpression of wt-
CaMKIIα in the SFO greatly potentiates the central acute AngII-mediated 
changes in blood pressure. We speculate that since CaMKIIα acts as a 
downstream molecule of AngII signaling in neurons, therefore increasing wt-
CaMKIIα expression will enhance the effects mediated by AngII on neurons, 
including reduction in K+ current and an increase in neuronal firing thereby 
leading to the rapid increase in blood pressure.  
                 Whereas the central AngII studies implicate the importance of wt-
CaMKIIα in the brain, to correlate it clinically with human essential hypertension, 
the functional relevance of wt-CaMKIIα overexpression in the brain was 
evaluated following chronic subcutaneous AngII infusion via osmotic minipumps. 
For these experiments mice received ICV injections of GFP and wt-CaMKIIα 
adenovirus following which osmotic minipumps were implanted to 




AdGFP injections showed the characteristic chronic AngII-induced increase in 
mean arterial pressure with a peak change of 31 mmHg. This gradual increase in 
blood pressure resembles the slow-pressor AngII-induced hypertensive model 
and closely correlates with human hypertension. Interestingly, mice with wt-
CaMKIIα overexpression had a significant increase in blood pressure 
immediately following AngII minipump implantation and continued to rise over the 
course of AngII infusion with a peak change of 39 mmHg. We posit that 
overexpression of wt-CaMKIIα in the brain sensitized these mice to an immediate 
increase in blood pressure at an initial subpressor dose of subcutaneous AngII. 
There could be several possible explanations for this phenomenon. As discussed 
with the acute AngII data, overexpression of a downstream signaling molecule, 
such as wt-CaMKIIα, in the central AngII pathway, can simply potentiate AngII 
response following minipump implantation. Additionally, although CaMKII is 
thought to be downstream of the redox mechanisms, few studies have shown 
that CaMKII can also activate NOX and increase ROS generation via a positive 
feedback mechanism (225). Further studies are also needed to determine if wt-
CaMKIIα overexpression has any effect on the integrity of the blood brain barrier 
which may cause a rapid access of AngII, following subcutaneous infusion, to 
certain brain regions that are normally protected by the blood brain barrier. 
               Based on previous studies demonstrating the Ca2+/CaM independent 
sustained CaMKII oxidation in the cardiomyocyte CaMKIIδ isoform (181), we next 
generated an adenovirus overexpressing CaMKIIα (mut-AdCaMKIIα) with 




the CaMKII isoforms except CaMKIIα has paired methionine residues at 281/282 
position where as CaMKIIα has a cysteine at the 280 position. Since both 
cysteine and methionine are highly susceptible to oxidation because of their low 
pKa values, we mutated cysteine to an alanine and the methionine to a valine in 
order for CaMKIIα to become resistant to oxidation. To check whether mutation in 
these residues interfere with CaMKIIα expression we used Western blot analysis 
in CATH.a neurons that were transduced with mut-AdCaMKIIα at different MOIs. 
As seen with the wt-CaMKIIα adenovirus, transduction of the mut adenovirus had 
a significant overexpression of both total and phosphorylated CaMKIIα protein at 
10, 25 and 50 MOI. It should be noted that in order to be consistent with our wt-
CaMKIIα studies in vitro, we selected the 25MOI of the mutant adenovirus for our 
next set of cell culture studies. CaMKIIα gene expression was also detected 
using RT-PCR in CATH.a neurons following adenovirus transduction. Similar to 
the wild-type adenovirus data, mut-CaMKIIα did not interfere with transcription of 
the other CaMKII isoforms. These studies suggest that the mutant CaMKIIα gene 
is able to make a functional protein and does not act as a dominant negative 
mutation to inhibit the endogenous protein in CATH.a neurons. 
                We next investigated the effect of mut-CaMKIIα on the AngII-mediated 
reduction in K+ current in CATH.a neurons. While our studies with the wt-
CaMKIIα adenovirus clearly demonstrated that the AngII-mediated inhibition of K+ 
current was greatly exacerbated in wt-CaMKIIα overexpressing neurons, CATH.a 
neurons that were transduced with mut-AdCaMKIIα had similar change in K+ 




once again indicate that while in CATH.a neurons CaMKIIα may not be the major 
mediator of AngII downstream signaling, however, mutation of the oxidation 
susceptible residues of CaMKIIα attenuate the potentiated effects of wt-CaMKIIα 
on AngII-regulation of K+ current indicating the importance of CaMKIIα in AngII 
intraneuronal signaling.  
               Our in vivo studies with wt-CaMKIIα suggested that overexpression of 
wt-CaMKIIα in the SFO sensitizes mice to an immediate increase in blood 
pressure at an initial subpressor dose of subcutaneous AngII. To investigate the 
role of mut-CaMKIIα on the chronic AngII-induced hypertensive response, we 
injected either ICV AdGFP or mut-AdCaMKIIα prior to AngII minipump 
implantation. Interestingly, blood pressure in mice with mut-CaMKIIα went up 
immediately after minipump implantation as seen with wt-CaMKIIα 
overexpression; however, after 2 days the blood pressure declined and followed 
the characteristic AngII-mediated gradual rise in blood pressure as seen in 
AdGFP group. The peak change (28 mmHg) in mut-AdCaMKIIα group was 
modestly decreased than the AdGFP injected mice. However, the peak increase 
in blood pressure was significantly lower in the mut-CaMKIIα mice as compared 
to the wt-CaMKIIα overexpressed group. Heart rate did not change between the 
groups. The initial rise in blood pressure in the mutant group 1-2 days after AngII 
infusion may be explained as a result of the presence of activated 
(phosphorylated) CaMKIIα to some extent. It should be noted that although 
mutation of the two residues will inhibit oxidation in those specific residues 




autophosphorylated in its threonine residue and get activated. Thus, our data 
confirm that mutation of the redox-sensitive residues in CaMKIIα leads to the 
characteristic gradual increase in blood pressure with slow pressor AngII infusion 
with a modest decrease in the peak AngII response as compared with AdGFP 
group. Furthermore, mut-CaMKIIα prevents the initial sensitization in mice as 





Significance of Research 
 
Increasing prevalence of hypertension associated with a high morbidity and 
mortality rate is a worldwide epidemic that is persistently rising. As per the World 
Health Organization (WHO) an estimated 17 million deaths worldwide each year 
are caused by cardiovascular disease, and complications of hypertension 
account for 9.4 million of these deaths. In 2012, a report released by the Center 
for Disease Control (CDC) stated that within the United States an estimated 67 
million Americans have hypertension and of the 47 million people who are 
receiving current treatment for hypertension, only 31 million people have their 
blood pressure controlled by prescribed medications and/or lifestyle changes. 
This alarming statistics indicate that 16 million hypertension patients (34%) are 
non-responsive to the current hypertensive therapeutics. 
                 Chronic hypertension results in a myriad of pathologies such as end-
organ damage, including vasculature remodeling and dysfunction, cardiac 
hypertrophy, thrombosis, fibrosis, nephrosclerosis, atherosclerosis, 
neurocognitive disorders, retinopathy, and aneurysm. Since high blood pressure 
often has no symptoms, it is left untreated and uncontrolled hypertension is a risk 
for several cardiovascular diseases, such as heart failure, stroke, coronary artery 
disease, kidney disease, and peripheral vascular disease (5, 235). Currently, the 
available antihypertensive prescribed medications are the ones that regulate 
renin-angiotensin-aldosterone activity, sympathetic/parasympathetic tone, salt 
and water excretion by the kidneys, and the ion channels. One of the common 




reduce heart rate and blood pressure by blocking the effects of norepinephrine 
and epinephrine. However, many of these drugs can cause adverse side effects 
including dizziness, headache, insomnia, weakness and fatigue (231). In addition, 
a significant population of hypertensive patients is not able to control their high 
blood pressure in spite of taking a single or a combination of the above 
mentioned drugs. 
                Numerous studies indicate that cardiovascular diseases, such as 
hypertension and heart failure involves activation of the brain renin-angiotensin 
system and elevated levels of AngII, the primary effector peptide of the RAS 
(203, 204) AngII-intraneuronal signaling involves increased generation of O2
- 
which is involved in the regulation of neuronal ion channels, increased neuronal 
activation thereby leading to sympathoexcitation and increased blood pressure 
(83, 110). We therefore wanted to closely examine the AngII signaling 
mechanisms in the neurons in order to identify novel therapeutic targets for 
hypertension. Since, CaMKII has been identified previously as an important 
mediator of AngII downstream signaling in neurons (80, 81), we propose that 
AngII stimulation of neurons induce redox-modification of specific residues in 
CaMKIIα which leads to inhibition of K+ channel current and an increase in blood 
pressure following AngII infusion in mice. 
               Although CaMKII has been shown to be redox-sensitive and 
susceptible to oxidation in the cardiomyocytes in presence of AngII (181, 187, 220), 
the role of AngII in regulation of predominant neuronal isoform of CaMKII 




in neurons we generated adenoviruses to overexpress both a wild-type form of 
CaMKIIα (wt-CaMKIIα) and a mutant CaMKIIα (mut-CaMKIIα) in which specific 
redox-sensitive cysteine and methionine residues were mutated. Our studies 
suggest that overexpressing the wt-CaMKIIα in neurons exacerbated the AngII-
mediated inhibition of neuronal K+ current. Additionally, wt-CaMKIIα when 
overexpressed in the brain sensitized mice to a significant increase in blood 
pressure immediately following AngII infusion. In comparison, mut-CaMKIIα 
attenuated the AngII-mediation reduction in K+ current as compared to the wt-
CaMKIIα and overexpression of mut-CaMKIIα in the brain attenuated the peak 
AngII response in a mouse model of AngII hypertension.  
                Furthermore, our mass spectrometry studies using CATH.a neuronal 
cell culture media indicated that a single exogenous administration of AngII (100 
nM) is rapidly metabolized within 3 hours in the culture media and should be 
replenished every 3 hours to in order to maintain chronically elevated AngII 
levels. This is relevant for studies that examine AngII neuronal signaling in vitro 
as an attempt to identify mechanisms occurring in patients with hypertension or 
heart failure in which levels of AngII is chronically elevated.  
                In summary, our studies have identified CaMKIIα as a downstream 
target of AngII signaling in neurons. More specifically we demonstrated that 
mutation of redox-sensitive residues in CaMKIIα can attenuate the potentiated 
AngII-response in wt-CaMKIIα overexpressed CATH.a neurons. The AngII-
induced hypertensive response was also attenuated in mice with mut-CaMKIIα 




redox modifications of CaMKIIα as seen in previous studies with a different 
CaMKII isoform. Targeting these residues in CaMKIIα or preventing their 
oxidation may therefore identify novel therapeutic targets to treat hypertension or 
other diseases in which CaMKIIα is an important player and is susceptible to 
oxidation. 
 
Limitations of the study 
 
Although we believe that our studies have advanced the understanding of AngII 
signaling in neurons associated with AngII-mediated neurogenic hypertension, 
there are certain limitations of this study that we need to consider. One obvious 
limitation to our studies is the use of a single in vitro cell culture model. It is 
important to highlight that the catecholaminergic CATH.a neuronal cell line used 
in this study have been widely identified in the literature as exhibiting similar 
AngII-intraneuronal signaling mechanisms as primary neurons isolated from the 
hypothalamus and brain stem (14, 79). However, further investigation is needed 
with primary neurons isolated from the brains of AngII-infused hypertensive mice 
to determine the ROS-mediated CaMKIIα oxidation levels. In addition, neurons 
cultured from a variety of cardiovascular brain centers, including the area 
postrema, paraventricular nucleus and the rostral ventrolateral medulla, in 
addition to the subfornical organ, will also provide important insight into the role 
of CaMKIIα in AngII-downstream signaling in those brain regions. 




cultured in a 21% hyperoxic environment. This is important particularly for our 
studies as reactive oxygen species are generated by electron reduction of 
molecular oxygen. In addition, neuronal cells in the brain receive about 2-4% 
oxygen which is significantly less than the culture environment for CATH.a cells. 
An ideal in vitro neuronal cell culture environment for conducting these 
experiments would have been in an incubator with 2-4% oxygen and 5% CO2.   
             A major limitation of the study is that we were not able to differentiate 
between the different isoforms of CaMKII in mediating AngII intra-neuronal 
signaling. Although we are able to show that CaMKIIα is involved in AngII 
signaling and mutating oxidation-sensitive residues of CaMKIIα blunts the 
potentiated AngII-mediated blood pressure response and the AngII-induced 
decrease in K+ current; however, the involvement of other CaMKII isoforms, such 
as CaMKIIβ cannot be overruled. Infact, CATH.a neurons has greater levels of 
CaMKIIβ as compared to CaMKIIα as detected by RT-PCR. Future studies are 
needed to investigate role of different CaMKII isoforms in mediating AngII 
signaling in central neurons. 
            Another limitation of the study is that we did not perform central acute 
AngII injections with ICV mut-CaMKIIα in mice brain. Our wt-CaMKIIα adenovirus 
studies indicated that mice with wt-AdCaMKIIα had a greater increase in mean 
arterial pressure with central acute AngII injections. It would be interesting to see 
if mut-CaMKIIα prevents the increased rise in blood pressure following AngII 
injection. If there is still an increase in blood pressure in the mut-AdCaMKIIα 




in blood pressure is a result of active phosphorylated CaMKIIα where as the 






Although we believe our studies have provided important insight in AngII 
signaling in central neurons, future studies are required to better understand the 
redox regulation of CaMKIIα and its effect on AngII-stimulated central neurons. 
One limitation of our studies that needs to be addressed is the identification of 
specific residues in CaMKIIα that are important in mediating AngII responses in 
neurons. Based on previous studies in a cardiomyocyte isoform of CaMKII (181), 
we mutated the cysteine and methionine residues of CaMKIIα at positions 280 
and 281 respectively; however, mass spectrometry and proteomics approaches 
should be utilized to confirm our findings. Moreover, it would be interesting to see 
whether a single residue mutation of either the cysteine or methionine is as 
effective as the double mutant. Furthermore, one study has suggested that 
CaMKIIα, involved in nitric oxide-induced excitotoxic neuronal cell death, 
undergoes S-nitrosylation in two cysteine residues at positions 280 and 289 
(189). The study also suggested that mutation of either cysteine abolished the 
autonomous activity of CaMKIIα thereby indicating the importance of those two 
residues in CaMKIIα activation. It is therefore reasonable to believe that mutating 
C289 in addition to our double mutation model may have a greater attenuation of 




              Another important question that needs to be addressed is the role of 
specific oxidants in mediating post-translational modifications of CaMKIIα. 
Anderson et al. showed that CaMKIIδ undergoes oxidation in the paired 
methionine residues in the presence of H2O2 (181). Studies from our lab show that 
AngII increased CaMKII phosphorylation in CATH.a neurons and overexpression 
of MnSOD attenuates the AngII-mediated CaMKII phosphorylation (83). 
Preliminary studies in our lab also suggest that CaMKII oxidation increases within 
30 minutes in presence of AngII stimulation; however, the specific role of O2
- or 
H2O2 in mediating CaMKIIα oxidation is still not clear. Further studies are needed 
to overexpress specific ROS scavenging enzyme in order to tease out their role 
in AngII-mediated CaMKIIα oxidation. More specifically, experiments should be 
done in CATH.a neurons with adenovirus overexpressing superoxide dismutase 
(SOD) to scavenge O2
- to determine their role in mediating CaMKIIα oxidation. 
Since dismutation of O2
- generates H2O2, it is important to use a specific H2O2 
scavenger such as, catalase or glutathione peroxidase (GPx). Co-transfection of 
adenovirus overexpressing SOD and catalase should be utilized to determine 
whether the effect is due to scavenging O2
- or producing high amounts of H202.           
Furthermore, previous reports indicate that AngII stimulation may increase H2O2 
levels through NOX activity, monoamine oxidase activity, or from mitochondrial 
respiration coupled to endogenous SOD (236, 237). Additionally, since S-
nitrosylation of CaMKIIα causes autonomous CaMKIIα activity (189), it would be 
interesting to see the functional relevance of overexpressing the different 




cytoplasmic, investigating the effect of scavenging oxidants in specific subcellular 
compartments on CaMKIIα oxidation is also important. Apart from targeting 
cytoplasmic ROS mitochondrial targeted SOD and catalase can be utilized to 
specifically scavenge mitochondrial O2
- and H2O2 and CaMKIIα oxidation levels 
can then be measured. 
               Future studies should also aim at evaluating some of the mechanism 
regulating CaMKII oxidation. For example, oxidation of methionine residues leads 
to formation of methionine sulfoxide which can be reversed by methionine 
sulfoxide reductases (Msr) (176). Infact, methionine sulfoxide reductase A 
knockout mouse (MsrA-/-) show increased CaMKIIδ oxidation with AngII and 
ishemic stress response (181)  However, the role of Msr in AngII intra-neuronal 
signaling and AngII-induced hypertensive response is not clear. The expression 
levels and activity of these enzymes in cardiovascular regulatory brain nuclei, 
such as the subfornical organ in case of AngII-infused hypertensive model is not 
known. It would be interesting to see if overexpression of Msr in neurons is able 
to prevent the potenetiated AngII-response and the increased blood pressure in 
mice. 
             Studies by Hongpaisan et al. have shown that in hippocampal neurons, 
increased mitochondrial O2
- activates CaMKII and increases CaMKII kinase 
activity (190). They also demonstrated that the increased kinase activity is 
mediated at least in part, by suppressing protein phosphatases, such as PP1 and 
PP2A. Since CaMKII is classically activated by autophosphorylation in Thr 286 




deactivating CaMKII by dephosphorylating the threonine residue. In our 
preliminary studies we found that AngII inhibits PP2A activity in CATH.a neurons 
without affecting PP2A protein expression. Western blot analysis for all three 
subunits of PP2A demonstrated that AngII does not change protein expression of 
PP2A subunits. However, overexpression of MnSOD to inhibit mitochondrial O2
- 
attenuates the AngII-mediated decrease in PP2A activity. Since, protein 
phosphatases are also known to be redox-sensitive (179, 180), future studies are 
needed to determine ROS-mediated PP2A modification which might explain the 
AngII-induced decrease in PP2A activity.  
                 Our studies elucidated that overexpression of wt-CaMKIIα 
exacerbates the AngII-mediated inhibition of K+ current in CATH.a neurons. In 
addition the mut-CaMKIIα is capable of attenuating the potentiated AngII 
response in wt-CaMKIIα transduced neurons. Although the RT-PCR data for the 
different voltage-gated K+ channels show that wt-CaMKIIα overexpression 
increases the basal expression of these Kv channels, further studies must be 
done to determine their protein expression in addition to cellular localization. 
Among the several targets of CaMKII, one of the important target are the ion 
channels and so direct regulation of Kv channels by CaMKIIα could be assessed 
in CATH.a neurons. Co-immunoprecipitation experiments could ascertain if 
CaMKIIα directly interacts with Kv channels and phosphorylates them. It was 
previously reported that AngII downregulates Kv4.3 in CATH.a neurons and also in 
the RVLM of rats with chronic heart failure (85). It is therefore important to 




other Kv channels is attenuated with mut-CaMKIIα overexpression. 
                Additionally, one of the most exciting future experiments would be to 
identify other proteins that are modulated by O2
- in presence of AngII. ROS are 
known to regulate a number of proteins by modifying their amino acid residues 
within their active sites. An exciting future investigation would be to determine 
whether ROS can directly act on ion channels to post-translationally modify them 
and regulate the flow of ions. It is known that in neurons H2O2 accelerates the 
Ca2+ channel opening in the plasma membrane by oxidizing certain subunits 
within the channel complex. Studies by Zimmerman et al. have demonstrated 
that the AngII-mediated O2
- is involved in the increased influx of extracellular 
Ca2+ through voltage-gated Ca2+ channels (84). It is therefore important to know 
whether O2
- or H2O2 play a direct regulation of either the Ca
2+ or the K+ channels 
in neuronal cells. Furthermore, Sumners and colleagues have clearly identified 
PKC as a downstream mediator of AngII signaling in neurons (14, 79). Since 
PKCs are also Ca2+ dependent enzymes and have active site cysteines it is 
reasonable to believe that PKCs are susceptible to ROS-mediated oxidation. In 
fact reports have previously shown that in different cell types ROS can act either 
upstream or downstream of PKCs thereby amplifying the response. For example, 
PKC can activate NADPH oxidase thus increasing the generation of ROS which 
in turn activate and regulate PKC function (238). These are exciting and critical 
studies that will build upon the novel findings of our studies.                         
              In addition to ROS, reactive nitrogen species (RNS) has also received 




system. Nitric oxide (NO) plays an important role in cardiovascular regulation by 
causing vasodilation in the periphery. In the cardiovascular regulatory regions of 
the brain, NO acts through a GABA-dependent mechanism to induce sympatho-
inhibition that decreases blood pressure and heart rate (239). In a diffusion-limited 
reaction O2
- has the ability to quench endogenous NO and form peroxynitrite 
(OONO-) thereby reducing NO bioavailability. As opposed to NO, OONO- is 
considered to be a toxic and powerful oxidant with known pathological 
consequences (240, 241). ONOO- is also potent in causing irreversible protein 
nitration thereby changing the biological function of the target protein. Hence, the 
role of ONOO- on CaMKIIα or other downstream molecules of AngII-signaling 
could reveal other possible redox modifications of those proteins. Therefore 
unraveling these AngII-redox mechanisms within the CNS will be crucial studies 
to pursue.  
                 Additional research is also needed to determine the role of reactive 
carbonyl species (RCS) on CaMKIIα and other downstream targets of AngII-
intraneuronal signaling and their subsequent involvement in neuro-
cardiovascular diseases. Reactive carbonyl species, such as acrolein, 
methylglyoxyl, malondialdehyde, 3-deoxyglucosome, and 4-hydroxy-2-alkenals, 
are small diffusible aldehydes or ketones that are generated from oxidation of 
lipids, glucose, and amino acids. Although the importance of RCS in 
cardiovascular disease is unclear, it may be possible that the RCS act as the 
primary mediators of dysfunction and damage (242-245) whereas ROS are the 




antioxidants trying to target the ROS have failed. In future studies, we could 
overexpress glutathione S-transferases, aldose reductase, aldehyde 
dehydrodenase, and glyoxylases to degrade RCS and determine their functional 
relevance in mediating post-translational modifications of CaMKIIα or other 
downstream signaling molecule of AngII in central neurons.  
             In summary, we believe that our studies have demonstrated the 
importance of CaMKIIα in mediating AngII-signaling in neurons and the AngII-
induced hypertension. Importantly, our studies have opened the door for an 
extensive series of both in vivo and in vitro future experiments designed to 
better understand the role of redox-sensitive proteins in central AngII signaling. 
In performing these additional studies, it is our hope that novel therapeutics will 
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